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1. ABSTRACT 
Antibodies are molecules able to specifically bind a particular antigen. Thanks to this 
capability they are extremely useful in many application. Indeed, antibodies are utilized in 
different routinary experiments, such as: Western blot, Enzyme-linked immunosorbent 
assay (ELISA), Immunohystochemistry, Immonofluorescence, Flow-cytometry, 
Immunoprecipitation, etc. Obviously, to carry out a good experiment a good antibody is 
needed. Indeed, many commercial available antibody aren’t efficient and leads to wrong 
results. This problem derives from a wrong antibody selection, production and validation. 
This project is aimed at setting up a selection, production and validation platform for 
polyclonal antibodies. In particular, the polyclonal antibodies were selected, in form of 
scFv, with a phage/yeast display combination, produced in yeast cells as minibody with a 
CH2-CH3 of rabbit IgG, validated with high-throughput technologies. A list of 78 proteins 
based on proteins structure and solubilization was drafted. Of these proteins only the first 
seven were used for scFv selection with two rounds of phage display and two additional 
rounds of yeast display. The selected scFvs were cloned in a yeast expression vector that 
allows the production of scFv fused to a rabbit IgG constant part. The collected yeast 
supernatants, containing the polyclonal, were sent us for the validation step. The polyclonal 
antibodies validation consists of three different analysis: Western blot, ELISA and protein 
microarray. From this validation arose that five polyclonal antibodies were highly specific 
and sensitive to the target protein, revealing that the entire platform is efficient. 
Furthermore, one of them was compared to the commercial ones using ELISA and protein 
microarray technologies. Only with protein microarray it could be possible observed that 
the commercial polyclonal presented cross-reactivity to other proteins. Instead, the yeast 
polyclonal resulted specific only to the target protein. This result confirmed that the 
selection with phage/yeast display combination is extremely specific avoiding the selection 
of sticky or unspecific antibodies. Moreover, protein microarray resulted a very useful and 
sensitive antibody validation technology. The second aim of this project concerned the use 
of a new technology to perform high-throughput antibody validation. Indeed, protein 
microarray is a successful tool, but present some drawbacks, such as production and 
purification of all the tested proteins and possible degradation of them once immobilized. 
These problems are overcome by a new technology called in situ protein array. This 
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technology consists of: cDNA immobilization on the slide; expression of the proteins of 
interest by in vitro transcription and translation system; capture the nascent proteins; 
reveal the proteins. Different types of in situ protein array have been set up, but the one 
used in this project is called protein array on demand. The peculiarity of this array is the 
presence of the capture agent directly on the template DNA. In this way only the DNA has 
to be printed on the slide. First, a DNA plasmid suitable for this system was constructed 
and subsequently tested with four different proteins available in our laboratory. 
Subsequently, a protein array on demand was performed, following the published method. 
The analysis showed that protein array on demand was less efficient and reproducible. For 
this reason a new protein array on demand was set up. The array slide, template and IVTT 
system were analyzed and tested to perform the best protein array on demand conditions. 
After different experiments the array on demand was performed using: CodeLink slide; 
biotinylated PCR DNA mixed with streptavidin; IVTT based on rabbit reticulocytes lysate. 
Since that the array was performed with an anti-tag antibody, an additional array was 
performed using an anti-GFP antibody direct against the eGFP. Even if the signal wasn’t 
high it could be affirmed that this protein array on demand was functional and better than 
the previous ones. In conclusion, a new protein array on demand was set up and can be 
potentially used for antibody validation. 
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2. INTRODUCTION 
 
2.1 THE ANTIBODY MOLECULE 
 
 
Antibodies, also called immunoglobulins, are molecules produced by B cells of the immune 
system. The main activity of an antibody is to disrupt the pathogen presents in the 
organism through two different mechanisms: opsonization and neutralization. These 
mechanisms involves the antibody binding to a particular antigen in a strong manner. The 
main type of immunoglobulin used in research is the G (IgG) and it is a protein composed of 
two polypeptide chains link together by covalent binding [1] (Fig. 1). In every polypeptide 
an heavy and a light chain is present. The heavy chain is composed by three constant 
domains called CH1, CH2 and CH3 and a variable domain called VH. The CH1 and CH2 domains 
are linked together by covalent binding, forming a flexible hinge region. On the other hand, 
the light chain is composed only by two domains, one variable (VL) and one constant (CL). 
The antibody’s part that confers the antigen specificity is the variable region (VH and VL), in 
particular three loops, called complementarity determining region (CDRs) 1,2 and 3, are 
responsible of the antibody diversity [2]. Finally, the constant region is responsible for 
glycosylation which is important for the recognition of effector molecules, such as 
immunoglobulin receptors or C1 complement complex. 
                                            
Figure 1. IgG structure and other antibody format. Structure of a full-length IgG and the possible 
smaller formats used in research: Fragment variable (Fv); single-chain fragment variable (scFv); 
Fragment-antigen-binding (Fab); minibody. 
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The scientific interest in antibodies arising from their ability to specifically recognize a 
determined target. The production of these molecules is not simple due to the higher 
molecular weight and post-translational modifications in the constant part. For this reason 
other antibody formats have been constructed maintaining the antibody specificity region 
(Fig. 1) [3]. The most used in research are: 
1. Fragment-antigen-binding (Fab), composed by CH1 and VH link with random and flexible 
peptide linker to VL and CL (50kDa);  
2. single-chain fragment variable (scFv) molecules, formed by VH and VL link with a linker 
peptide of 15aa (25-30kDa);  
3. fragment variable (Fv), only VH and VL are linked without a linker between them 
(25kDa); 
4. minibody, formed by scFv-CH3 protein that self-assembled into a bivalent dimer 
(80kDa).; 
5. ScFv-Fc, bivalent molecule composed by two scFvs fused to CH2-CH3 IgG region 
(120kDa). 
 
 
2.2 THE IMPORTANCE OF ANTIBODIES SPECIFICITY IN RESEARCH 
 
The Human Genome Project, in 2000, has revealed a great number of genes that were 
previously unknown and subsequently shifted the attention from the genome to the 
proteome. The major approach to explore the whole human proteome is the use of affinity 
reagents, among which antibodies are the most widely used. Antibodies are able to 
recognize specifically a selected antigen. It is possible to produce antibody directed to a 
particular epitope (monoclonal) or different epitopes of the same antigen (polyclonal). 
Furthermore, antibodies can be easily marked with many kind of molecules such as: 
enzymes, fluorophores, biomolecules and drugs. All these features have lead to the use of 
antibodies in various research fields. Indeed, they are necessary for many standard 
analysis such as:  
 Western blot (WB), where antibodies allow the recognition of denaturated proteins 
present in a lysate or protein mix; 
 Enzyme-linked immunosorbent assay (ELISA), in which antibodies reveal the 
presence of full-lengh proteins on plastic plates; 
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 Immunoprecipitation (IP), where antibodies are not only used to detect the protein 
presence, but also to precipitated protein complexes; 
 Flow-cytometry (FC), in which marked antibodies allow proteins recognition on 
cells or different marked antibodies can allow the separation of different cells; 
 Immunohistochemistry (IHC), where tissues are stained with antibodies allowing to 
study  tissue structure and cells distribution; 
 Immunofluorescence (IF), in which tissues are depicted with antibodies conjugated 
with a fluorophore allowing us to compare not only  protein distribution in different 
cells types but also cancerous cells with normal ones.  
Antibodies are also employed in many new techniques. For example, they are very 
important in protein microarray technology, where they are used to detect the expression 
of proteins in different samples or cell lysates [4; 5; 6]. Recently, they have been used to 
address in specific tissue nanoparticles carrying drugs or other molecules [7; 8; 9]. 
Furthermore, antibodies are also utilized for the isolation of specific cells, such as stem 
cells [10; 11]. Obviously, all these analysis are based on  the antibody specificity. Indeed, 
antibodies that recognize the wrong molecules or cross-react against other antigens will 
cause an incorrect result. These problems occur in the case of non-specific validation. 
Moreover, some analysis can’t be carried out because an antibody, against the specific 
antigen, is not available. For this reason, another technology has been introduced for 
proteome analysis: mass spectrometry (MS)[12]. The main ability of MS is the analysis of 
proteins without affinity reagents use. On the other hand, MS is not high-throughput and 
can’t be used in different applications, such as immunofluorescence and 
immunohystochemistry, for this reason technologies using antibodies are preferred. In the 
last decade, many articles have reported the inefficiency of different commercial antibodies 
[13; 14; 15]. This is the result of a validation tested only with few experiments. Indeed, 
many antibodies can have diverse sensibility in different analysis. To overcome this 
problem the Human Protein Organization (HUPO) have started a Human Antibody 
Initiative (HAI) that have the aim to [16] :  
1. create a catalogue of validated antibodies produced by companies or academic research 
laboratories; 
2. create a protein atlas that collect the differences of protein expression in normal and 
disease tissue. 
For this purpose two public database have been accomplished. The first is called 
antibodypedia (www.antibodypedia.org) in which antibodies directed to 20767 gene 
 9 
products are collected. The website provides data about all antibodies recognizing a certain 
protein and also the different methods used for each analysis (WB, ELISA, IP,IHC, FC, IF). 
The second portal is the protein atlas (www.proteinatlas.org) that collects millions of high-
resolution images showing the spatial distribution of proteins in 44 different normal 
human tissues and 20 different cancer types, as well as 46 different human cell lines. The 
data is combined with validation performed for each antibody, including WB and IM 
analysis and, for a large fraction, a protein array assay and immunofluorescent based 
confocal microscopy (Fig. 2). For every protein searched information about expression 
profiles, protein classes and chromosome location are supplied. At the moment, 20329 
gene products are collected in that portal.          
         
 
 
Figure 2. The human protein atlas [17]. Example of the data gives by the protein atlas database. 
 
These two database are very useful for antibody research and utilization, even if many 
target remain without a specific antibody. For this purpose high-throughput antibody 
production, selection and validation is needed.  
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2.3 IN VIVO AND IN VITRO ANTIBODIES PRODUCTION TECHNOLOGIES 
 
Antibodies are very powerful molecules in research, therapy and diagnosis. For this reason, 
it has been necessary to develop efficient methodologies to produce them. In 1975, Kohelr 
and Milstein have sewn up the “hybridoma method” (Fig. 3), based on B lymphocytes and 
tumoral cells fusion [18]. In particular, this method consists of the injection of a putative 
antigen and adjuvants in animals (mouse, rat or rabbit) to induce an immune rensponse 
that lead to antibodies production by B cells. When the animal sera is positive for 
antibodies against the antigen, the lymphocytes are collected and fused to tumoral cells to 
allow the formation of hybridomas. These cells are able to produce antibodies, such as B 
lymphocytes, and can reproduce itself in vitro for a long period, as a tumor cell line.  
 
                       
 
 
 
Figure 3. In vivo antibody production technology. A) The “hybridoma method” involves the use 
of animals (mouse, rat or rabbit). The hybridoma is a cell derived from the fusion of animal B cells, 
stimulated for antibody production through antigen injection, and tumor cells (myeloma). This cell 
type is able to produce antibody for long time in vitro allowing the antibody selection. B) Polyclonal 
antibodies production: animals (normally rabbit) are injected with the antigen supplemented with 
adjuvant and their blood is collected and the sera separated. Subsequently, the antisera can be 
purified with protein A, for IgGs separation, and peptide affinity column, for antigen specific IgGs 
separation. The polyclonals set can be subsequently tested.  
 
This method is normally used for monoclonal antibodies production. In case of polyclonal 
antibodies, the same animals are injected with the antigen, supplemented with specific 
A) 
B) 
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adjuvants, and after 7-14 days the animal sera is collected and used directly as polyclonals 
antibodies or successively purified [19]. These methods are the well known methodologies 
for antibodies production, but they still to be very laborious, expensive and time-
consuming. For these reasons in vitro methods have been developed. These technologies 
don’t involve the antibodies production by animals, but utilize antibody libraries. The 
library consists in a collection of antibodies cDNA that can be screen to select the one of 
interest. There are different types of antibody libraries differing each other in how they are 
made [20]:   
1. naïve; 
2. immune; 
3. semi-synthetic; 
4. synthetic. 
The naïve library derives from Ig of human donors or animals that are not immunized to a 
particular antigen. The light and heavy chains are amplified by polymerase chain reaction 
(PCR) and collected [21]. For this type of library the diversity is directly dependent to the 
number of the donors. On the opposite side the immune antibody libraries consist in the 
RNA amplification of immunoglobulins derived from immunized individuals or animals 
[20]. The semi-synthetic and synthetic libraries are based on random oligonucleotides 
synthesis to construct CDRs regions. In the semi-synthetic only a part of the antibody, 
normally the CDR3, is synthetic [22]. These last types of library are used to increase the 
library diversity. All these libraries contain at least from 107 to 1011 different antibody 
clones that can be used in all the in vitro antibody production technologies. In general, 
these methods are called “display technologies” and allow the linkage between genotype 
and phenotype. In this way the cDNA of the selected antibody is immediately avaliable for 
further applications. In vitro technologies, differently to the hybridoma method, allow a 
faster and easier selection and a major specificity of the antibodies selected has been 
shown [23]. Furthermore, in vitro antibody production allows to select antibodies against 
toxins and compounds that can’t be injected in the animals. In the last decade, different 
display technologies have been developed, most used are: phage display and yeast display 
[24; 25; 26]. These two techniques are based on the display of the antibody on the cell 
surface, fusing it with a cell surface protein. In case of phage display the glycoproteins III or 
VIII are used; for yeast display mannoproteins are the used ones. The corresponding 
antibody cDNA is present inside the yeast cell or phage particle.  
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2.3.1 PHAGE DISPLAY TECHNOLOGY 
Phage display is a technology that allows the selection of molecules through the exposition 
of peptides, proteins or antibodies on phage particles. The idea to use filamentous phages 
as an expression vector was introduced by Smith in 1985 [27]. Filamentous phages 
considered to be  a good expression vector because [28]:  
1. their genome can be modified, with insertion, without causing packaging problems;  
2. their genome can be isolated; 
3. they can tolerate stringent conditions necessary for selection steps; 
4. coat proteins can be fused to other molecules, without loosing their infective role; 
5. they can be accumulated in large amount in bacterial cells thanks to their non-lytic 
propagation. 
The main phage utilized for phage display is the filamentous phage M13 [29](Fig. 4).  
 
 
                    
 
Figure 4. Filamentous phage M13 structure. The M13 genome is a single stranded DNA of 6407 
bases. The DNA molecule is covered by the major coat protein gpVIII of which 2700 copies are 
present. On the opposite sides of the phage particle there are minor coat proteins: gpIII, gpVI, gpVII 
and gpIX. The proteins III and VI are located at one side and at the other there are gpVII and gpIX. 
The minor coat proteins are present in 5 copies each. A single phage particle is 1000nm in length 
and 5nm in diameter. 
 
 
It is composed by a capsid that holds a single stranded DNA (ssDNA) encoding for capsid, 
infection and cell cycle proteins. The capsid is formed by five proteins: gpIII, gpVI, gpVII, 
gpVIII and gpIX. The gpVIII, called major coat protein, is present in 2700 copies for each 
phage particle and covers the entire ssDNA molecule. The other proteins are called minor 
coat proteins because only five copies each are present in a single phage. They are situated 
at the double-ended of a phage particle: gpIII and gpVI at one side; gpVII and gpIX at the 
opposite one.  In phage display technology the gpIII and gpVIII proteins are generally used 
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for proteins exposition. A cDNA library can be directly inserted in the phage genome fused 
to gpIII or gpVIII gene [28] (Fig. 5). This allows the formation of phages containing each: 1. 
a DNA molecule containing the cDNA of a protein fused to phage protein; 2. the 
corresponding protein fused to all the copies of the phage protein. This method is potential 
only with peptides or small proteins because when big proteins, such as antibodies, are 
fused to gpIII or gpVIII the phage packaging or infection is compromised. To overcome this 
problem a new method was introduced. This new method uses a different vector called 
phagemid for protein display [30](Fig. 5). The phagemid is a plasmid containing: 
1. phage replication origin; 
2. packaging signal; 
3. gpIII or gpVIII gene fused to the cDNA library. 
The phagemid is transformed in the bacteria cell that will be infected by a helper phage 
containing wild-type phage genome. The resulting phages will have internalized the 
phagemid and will present only some copies of gpIII or gpVIII fused to the displayed 
protein [24].  
 
                  
 
Figure 5. Phage display vectors. Phage display technology can be carry out with two different 
strategies. A)Phage vector: the cDNA library (blue) is directly inserted in the phage genome, fused 
to the gpIII gene (red). The resulting phages will present as genome the phage vector containing the 
cDNA of a protein X fused to the gpIII gene; as phenotype, the same protein X (blue) fused to all the 
gpIII copies (red). B) The phagemid vector is a plasmid containing the gpIII gene (red), the 
packaging signal (yellow) and the M13 ori (green). The cDNA library is inserted in this plasmid 
fused to the gpIII gene. To infect the bacteria a wild-type phage, called helper phage, is needed. 
Since that also a wild-type gpIII gene is present during the infection, only some gpIII copies (red) of 
the nascent phages, containing the phagemid vector, will be fused to the X protein (blue). 
 
 
A) B) 
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When a library is expressed with phage display it has to be selected to find the cDNA 
fragments of interest. The selection stage is called biopanning and consists of three steps 
(Fig. 6)[28]: 
1. target immobilization: the antigen is bound on a solid support; 
2. phage binding: exposure of the phage presenting antibody to the antigen; 
3. removing unbound phages: washes to eliminate aspecific phages;  
4. phage elution: the phage positive for antigen binding are eluted using free antigen or a 
competitor. 
Normally, these steps are repeated three times with more stringent washing conditions to 
eliminate the major amount of unspecific antibodies.  
 
                       
 
Figure 6. Biopanning of a scFv phage library. To select the phage presenting the antibody (scFv) 
of interest is necessary to perform rounds of selection. The selection consist in: 1. target 
immobilization; 2. phage binding; 3. removing of the unbound phages; 4. elution. This allow the 
enrichment of the phages carrying the scFv recognizing the target. 
 
 
Phage display technology is a potential tool that can be used for different applications, but 
the main remains protein-protein interactions, in particular antibody-antigen. In antibody 
phage display a Fab or scFv can be expressed. Antibody libraries, containing 1011 clones, 
can be immediately use for display selection to find antibody with high specificity [30]. 
After the bacteria infection the phages displayed antibodies are collected and subsequently 
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selected against the specific antigen. It has been also demonstrated that with phage display 
specific antibodies against protein, haptens and complex antigens, as carcinoma cells, can 
be isolated [31]. Furthermore, monoclonal antibodies optimized with phage display 
technology are now used for clinical purpose, such as Motavizumab and Palivizumab, 
humanized antibody direct against respiratory sinchythial virus (RSV) [32]. Its has been 
reported that approximately 30% of all human antibodies now in clinical trial are derived 
from phage display [33]. This confirms the great specificity of phage display derived 
antibodies. 
 
 
2.3.2 YEAST DISPLAY TECHNOLOGY 
Another display technology that utilized organism as display system is the yeast display. 
Yeasts are unicellular eukaryotic organisms that have a generally-regarded-as-safe status 
(GRAS). The yeast cell is characterized by all the typical eukaryotic compartments such as: 
mitochondria, nucleus, endoplasmic reticulum, lisosomes, vesicles and Golgi apparatus 
(Fig. 7).  
 
                          
 
Figure 7. Yeast cell. Structure of a yeats cell. In the citosol are present: nucleos, endoplasmic 
reticulum, lipid granules, microtubules, Golgi apparatus, vacuolar membrane, vesicles and 
mitochondria. Al this compartments are covered by two layer: plasmamembrane and the cell wall.  
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All these elements form the cytoplasm of a yeast cell that is cover by a plasma membrane. 
The plasma membrane is in turn covered by a thick layer called cell wall and the space 
between them is called periplasmic space. The cell wall is 200nm thick and is principally 
composed by mannoproteins and β-linked glucans [34]. The proteins normally choose for 
yeast display are mannoproteins. Two types of them are present in yeast:  
1. Extractable with SDS (associated with glucans through non-covalent binding); 
2. Extractable only with glucans digestion (associated with glucans through covalent 
binding). 
Only the second type of mannoproteins is used for yeast display, in particular the most 
used are: α-agglutinin, a-agglutinin and flocculins [35]. All these proteins have a  
glycosylphosphatidylinositol (GPI) anchor that is important for cell-surface protein 
expression. In yeast display the cDNA library cloned in yeast plasmid contains [36]: an 
inducible promoter, a secretion signal and the cDNA library fused to the mannoprotein. If 
the display is carried out with α-agglutinin or flocculin 1p only the C-term half part, 
correspondent to the 3’ half of the gene, is present in the plasmid, because in this part is 
present the GPI anchor signal that is essential for the cell wall attachment (Fig. 8 A,B). 
When the display is carried out with the a-agglutinin the Aga2 gene is fused the library 
instead Aga1 gene is present in the yeast genome (Fig. 8 C). The Aga1 and Aga2 domains 
are linked together through covalent binding.  
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Figure 8. Yeast display vectors. Different proteins are used for yeast display selection. The most 
utilized are: a-agglutinin, α-agglutinin and flocculin. In case of α-agglutinin (A) and flocculin (B) the 
library is fused to the 3’ half part of the corresponded gene, allowing the expression of the GPI 
anchor the C-terminal part of the mannoproteins and the displayed protein. The a-agglutinin 
protein is composed by two domains translate by two different gene Aga1 and Aga2. in this case the 
library is fused to the Aga2 gene and the Aga1 is present in the yeast genome (C). 
 
 
The plasmid is present in multiple copies in the yeast cell and it has been demonstrated 
that almost 105-106 copies of  mannoprotein are presenting the target gene [35]. After the 
library expression a selection step is necessary. In yeast display the selection is achieved 
with magnetic bead and flow-cytometric sorting. The magnetic beads are used to decrease 
the size of the library, that is too much for flow-cytometric sorting. The employment of 
high-speed flow-cytometry allows the detection of the amount of protein expressed by 
yeast and the affinity to the target using a two-color labeling scheme. The resulting graph 
shows (Fig. 9) [37]:  
1. yeast displaying protein with less affinity to the target (black line); 
2. yeast displaying protein with high affinity to the target (green line); 
Yeast vector Yeast cell 
A) 
B) 
C) 
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3. yeast displaying no express of proteins (blue line); 
4. yeast displaying proteins with no binding activity to the target (yellow line). 
 
                                    
 
Figure 9. Yeast displaying scFv selection with flow-cytometry cell sorting [37]. Flow-
cytometric analysis of yeast displaying scFv. The double-color detection allows to distinguish yeast 
for antigen binding and scFv expression on the yeast surface through anti-tag antibody (c-myc). 
 
 
Since its introduction 10 years ago [38], yeast display has been used to express a variety of 
proteins for improved affinity, specificity, expression, stability, and catalytic activity. More 
recently, it has been widely used for antibody selection and engineering [37; 39]. It has 
been demonstrated that the distribution of affinity of antibodies selected by yeast display is 
similar to the antibodies isolated with phage display. Furthermore, yeast display is suitable 
for antibody affinity maturation [40].  
 
 
2.3.3 DIFFERENCES BETWEEN PHAGE AND YEATS ANTIBODY DISPLAY 
Either phage and yeast display are powerful tools for high specific antibody selection and 
maturation. Phage display was introduced a decade before yeast display and many paper 
have been published using these technologies [41] (Fig. 11). 
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Figure 11. Phage and yeast display publications [41]. Number of publications regarding phage 
and yeast display by their discovery to 2008. 
 
 
The main differences between phage and yeast display are:  
1. type of organism: phage is a prokaryotic and doesn’t allow the expression of complex 
proteins or post-translational modifications. Yeast is an eukaryotic organism. 
2. safety: phage is a virus, and because of this not a safe organism; yeast has a GRAS. 
3. library dimension: phage allows the use of largest libraries till 1011 clones; yeast uses 
smaller library. In yeast display additional rounds of magnetic-cell sorting are needed 
for the selection of largest library. 
4. number of protein copies express by a single cell: using a phage vector is possible to 
have a maximum of 2700 copies displayed on a single phage, but it is true only for small 
proteins. With yeast display till 105-106 protein copies can be present on a single cell. 
Recently, to exploit the advantage of the two technologies, researchers try to couple them. 
In 2011, Patel et al. have introduced a cross-species display system in which phage and 
yeast display are used in parallel to antibody library selection [42]. In this paper an 
adapter-direct display platform have been used. In this platform two different vectors are 
used: display vector and helper vector. The display vector avoids the anchoring sequence 
and can be used to display proteins on different species in combination with the helper 
vector that is species-specific. Using this technology Patel and coworkers have selected 
antibodies with a Kd in the nanomolar order. Furthermore they observed that the first 
round of selection with phage panning allows the enrichment of the library to 106; this 
permits the directly use of FACS for yeast selection. Another methodology, that combines 
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phage and yeast display, was published in 2012 by Ferrara et al. [43]. In this paper the 
researchers have selected antibodies against the antigen 85 of tuberculosis bacteria 
through two round of phage selection followed by one or two round of yeast display 
selection using FACS analysis. The passage between phage and yeast vector has been 
achieved by homologous recombination. In conclusion the combination of the two display 
method seems to improve the potential of both technologies. 
 
 
2.4 ANTIBODY VALIDATION 
 
The great use of antibodies in research has brought to the development of high-throughput 
production, selection and validation methods. If the antibody production is well 
characterized, the validation has been underrated. Many articles take a lot of attention in 
the antibodies production and selection and don’t perform a real antibody validation. 
Indeed, as often as not the validation is carried out with Western blot and ELISA test only. 
For this reason many antibodies can be not functional in immunohistochemistry or show 
cross-reactivity if used in more sensible technique such as protein microarray. To validate 
antibodies there isn’t a standard protocol because they have to be choosen depending on 
the experiment that has to be performed. From this point of view, Rimm’ s laboratory has 
developed an algorithm for antibody validation for immunohistochemistry/quantitative 
immunofluorescence that can be used also for other application [15](Fig. 12).  
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Figure 12. The Rimm’s algorithm. The part upper the dot line concern the antibody validation cell 
lines for antibody specificity testing. The lower part consists in further validation with tissue 
microarray for localization of the antibody target and to test different antibody lots.  
 
 
This algorithm starts from the validation in Western blot of different cell lysates that 
express the target protein. This part allows to test the specificity of the antibody using 
techniques such as IP or short interfering RNA (siRNA). Subsequently the antibody will be 
used for in immunohistochemistry test to verify their reproducibility and the capability to 
localize the target in every tissue expressing it. Tissue microarray and protein microarray 
are emerging as important tool for antibody validation [44; 45]. Indeed, in 2012 Sjöberg at 
al. have shown the validation of monoclonal, polyclonal and scFv antibodies against protein 
containing SH2 domain using high-throughput protein microarray [46]. This technology is 
very useful because is sensitive and allows to test an antibody on thousand of characters in 
a single experiment. 
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2.5 PROTEIN MICROARRAY TECHNOLOGY 
 
The great interest arisen by proteome studies have led to development and improvements 
of different highly innovative technologies. In particular, there was a need to developed a 
method that increase the number of characters analyzed in one experiment, with less 
consumption of materials and solutions. One of the major tool that has been set up for 
proteomic studies is protein microarray. This technology allows the immobilization of 
thousands of proteins on a solid surface, in a miniaturized format, and their analysis, in 
parallel, in a single experiment. Every kind of proteins can be immobilized on a microarray 
slide: peptides, full-length proteins, antibodies, receptors, enzymes or aptamers. As solid 
support, slides made of glass, polymer or plastic are used. This support is subsequently 
treated to allow the protein immobilization through different types of binding (Fig. 13): 
 Non-covalent (hydrophobic or entrapment: nitrocellulose, polystyrene; positive 
charges: poly-lysine); 
 Covalent (active groups such as: aldehyde, epoxy, esters, etc.); 
 Biomolecular interactions (streptavidin-biotin, His tag-nichel ions). 
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Figure 13. Proteins immobilization on different microarray slides. The proteins can be 
immobilized in different way on a solid surface. Non-covalent binding: proteins are capture through 
hydrophobic groups or entrap in a matrix (e.g. nitrocellulose). Covalent binding: proteins are 
immobilized through active groups such as epoxy, ester or aldhehyde that are able to form covalent 
bounds with all kind of proteins. Biomolecular interactions: the proteins are fused to tags or 
biomolecules such as biotin that permit the proteins capture by known groups or other molecule 
such as streptavidin. 
 
The deposition of proteins on the slide is called “printing” or “spotting” and can be achieve 
through particular instruments called array printer. These instruments utilized pins to 
permit the deposition of nanolitre of protein. The pins are divided in two type:  
1. contact pins: place nanolitre of sample directly on the slide surface; 
2. non-contact pins: deposit drops of sample using capillary or ink jet technology. 
Once the proteins are spotted they can be directly analyzed treating the slide with the 
desired solutions. The mainly detection method use with protein microarray is 
fluorescence, that is sensitive, safe and can be read with charge coupled device (CCD) 
camera or laser scanners. Although, other label methods are used, such as 
chemiluminescence and radioactivity. In recent years, also label-free methods have been 
used such as: mass spectrometry, surface plasmon resonance imaging (SPRI) and surface-
enhanced laser desorption (SELDI)[47]. Protein microarray technology allows also the 
quantification of the signals using positive and negative controls and a calibration scale. 
Non-covalent Covalent Biomolecular interaction 
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2.5.1 PROTEIN MICROARRAY APPLICATIONS 
Protein microarrays are subdivided in three main groups : 
1. analytical; 
2. functional; 
3. reverse-phase. 
The analytical arrays are used to profile protein affinity and expression in different cells. 
The most common analytical array is antibody array, where this type of protein is 
immobilized on the slide and a proteins mixture is the probe (Fig. 14). Functional arrays 
allow the detection of proteins function and interactions. Normally full-length or domains 
are spotted and analyzed with proteins or other molecules such as: DNA, RNA, lipids, 
carbohydrates and drugs (Fig. 14). Finally, reverse-phase array are used to detect altered 
proteins or to highlight proteome differences between two cell types or healthy and 
diseased cells. Indeed, this kind of array consists in the printing of a cell lysate that can be 
characterized using a specific antibody or proteins (Fig. 14).  
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Figure 14. Protein arrays subtypes. Protein microarrays are divided in three subgroups: 
analitical, functional and reverse-phase. Analytical arrays are normally used in protein expression 
analysis using antibodies as capture molecules. Functional arrays allow the analysis of protein 
function, interaction (DNA, lipid, drug, protein, RNA) or antibody validation and consist in the 
immobilization of full-length protein or domain. Reverse-phase array are characterized by 
immobilization of cells lysate instead of single molecules and are used in proteome analysis.  
 
It is immediately clear that protein microarray can be a powerful tool for many different 
applications. First it has been widely used for protein interaction studies that allow to 
understand signaling pathways [48] and to discover binding proteins [49]. Protein 
microarray are also important for clinical purpose because allows biomarkers and 
autoantigens discovery [50; 51], where healthy and diseased sera are used to screen 
proteins/peptides library. Furthermore, host-pathogens interface studies that lead to 
vaccine development can be carry out [52]. Another important fields in which protein 
microarray are widely used is antibody validation. Many times commercial antibodies 
seems to be less specific for their target and cross-reactivity can also be detect. These 
problems lead to a wrong or less accurate validation. Protein microarrays are potential tool 
for this purpose because provide multiplex analysis of different antigens revealing 
specificity and selectivity of the antibody. In 2008, A. Lueking and coworkers have shown 
Analytical Functional Reverse-phase 
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the characterization of a monoclonal antibody against  the variant 6 of CD44 molecule [53]. 
Sjöberg R. et al. have used protein microarray to validate selectivity and specificity of 
affinity reagents direct against SH2-domain[46]. In this study monoclonal antibodies, single 
chain fragment variable and polyclonal antibodies have been utilized as affinity reagents 
demonstrating that all these type of antibody format are feasible for protein microarray 
validation. Furthermore, they have shown that with protein microarray is possible to 
validate antibodies against proteins with 89% of similarity determine the exclusion of 
some aspecific monoclonals. Finally, it is possible to assure that protein microarray can be 
one of the major tool for antibody validation. 
 
2.5.2 PROTEIN MICROARRAY IMPROVEMENTS 
As described before, to perform a protein microarray is necessary to produce and purify all 
the proteins that have to be printed on the slide. This become an issue when you think to 
produce thousands of proteins in the same time. The development of protein libraries has 
allowed a more easily search of proteins cDNA but their production and purification 
remain a time-consuming issue. Furthermore, protein microarrays are not stable for long 
period so it is necessary to proceed with the experiment immediately after the spotting. 
Many groups of researchers have try to overcome these two problems link to protein 
microarray technology. The first innovation for protein microarray improvement was the 
use of cell-free protein expression systems, that are able to transcribed a DNA template and 
translate the correspondent mRNA in a protein [54]. The combination of this two tools has 
brought to a new technology called “in situ protein array”  [55]. This new type of protein 
microarray consists in the immobilization of DNA instead of proteins eliminating the 
stability issue. Once the DNA is spotted it can be translate in proteins directly just when is 
needed, erasing the protein production and purification processes. Even if standard protein 
array continue to be widely used, many groups took interest in this “in situ protein array” 
developing different strategy to use it. 
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2.6 PROTEIN PRODUCTION WITHOUT CELL BOUNDERIES 
 
Protein production is one of the key steps in biotechnology and functional proteomics. 
Conventional protein expression systems rely on prokariotic cells as bacteria, where the 
most used is Escherichia coli (E. coli) or eukaryotic cells as yeast, insect and mammalian cell 
systems [56; 57; 58]. The prokaryotic expression systems are easily adaptable to high-
throughput expression methodologies, but are less efficient in the expression of complex 
mammalian proteins, in particular those which require post-translational modification. At 
the opposite site, systems based on eukaryotic organisms  are capable of expressing post-
translationally modified proteins but are difficult to be integrated into high-throughput 
methodologies. In order to find a new method that allows an easier, cost-effective and high-
throughput application, cell-free based systems were developed [59]. In 1961 Niremberg 
and Matthaei have demonstrated the possibility to translate in vitro proteins with an E. coli 
extract using RNA or synthetic nucleotide as a template [59]. Subsequently, Zubay et al. has 
shown the coupled transcription and translation of a β-galactosidase chain using an E. coli 
extract and a virus DNA [60]. Compared to cell-based methods, cell-free expression 
systems are considerably faster since they don’t require cell transfection, cell culture and 
extensive protein purification procedures (Fig. 16A). Moreover, they don’t involve cell lysis 
steps that could denaturate proteins. In addition, cell-free systems allow the production of 
toxic, insoluble or membrane proteins, that are difficult to produce using cell-based 
methods. Finally, they can be used in a microlitre scale, making them ideal for high-
throughput applications [61; 62].  
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Figure 16. Protein production systems. A) Protein expression with in vivo or in vitro methods. In 
case of in vivo (bacteria) cells have to be cultivated, induced and collected; subsequently a cell lysis 
has to be carried out and in some cases also protein solubilization is needed. All these passages 
takes 3 days. When an in vitro expression system is used the protein production takes only 2 hours 
and the extract necessary for the expression has to be prepared only 4 times /year. B) Schematic 
representation of the passages occurring during an IVTT reaction [63]: DNA template has to be 
transcribed in mRNA with all the transcription complex, RNA polymerase and energy sources; the 
mRNA is translate in protein using amminoacids, tRNAs, ribosome and energy sources. 
 
The most recent in vitro transcription and translation (IVTT) systems are composed of 
crude cell lysate supplemented of [64] (Fig. 16B):  
1. energy sources (ATP, ADP); 
2. RNA polymerase (T7, SP6 or T3) ; 
3. amino acids; 
4. tRNA; 
5. enzymes; 
6. NTPs ; 
7. salts and ions.  
In vitro expression 
In vivo expression 
A) B) 
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Initially, only E. coli lysate was used, because it is easier to grow in a large scale and it is 
also less expensive. Successively, IVTT systems based on eukaryotic extracts, as rabbit 
reticulocytes and wheat germ, were generated [65]. These systems seem to be more stable 
than the E. coli one and more suitable for eukaryotic protein production. Recently, also 
insect and human cells lysates have been developed, showing an improvement in terms of 
protein quantity [66; 67]. The major advantage of cell-free systems is their flexibility that 
has allowed significant improvements in protein yields, folding and post-translational 
modifications through the addiction of chaperons or specific enzymes (glycosylation, 
phosphorilation, etc.) to the cells extract [68]. Thanks to all these improvements, IVTT 
systems are increasingly used in protein array technology, protein structural studies, large 
scale analysis of proteins, screening of antibody mutants, IVEC technology and display 
technologies such as ribosome display, mRNA display and in vitro compartimentalization  
[55; 62; 69; 70; 71].  
 
2.7 IN SITU PROTEIN ARRAY 
 
The great innovation of protein production in a cell-free mode and the possibility to 
transcribe and translate a DNA template in a single step has allowed the generation of high-
throughput technologies, such as in situ protein arrays. These particular microarrays 
permit to build the protein array whenever is needed, starting from a DNA template. An in 
situ protein array consists of four different steps (Fig. 17): 1) immobilizing a DNA template 
on a solid support (Fig. 17A); 2) treating the support with an IVTT mixture (Fig. 17B); 3) 
capturing the nascent protein on the solid support (Fig. 17C); 4) revealing the protein of 
interest (Fig. 17D). In this way the standard protein array drawbacks of protein stability 
and long period of storage are overcome. The first in situ protein array which has been 
developed is the protein in situ array (PISA), also known as DiscernArray, by He and 
Taussing in 2001[55]. Afterwards, many other in situ protein arrays have been developed: 
Nucleic acid programmable protein array (NAPPA) [72], multiple spotting technique 
(MIST) [73], TUS-TER array [74], DNA array to protein array (DAPA)[75], in situ 
puromycin-capture from mRNA array [76]. 
                                          
 
 30 
                                            
 
Figure 17. In situ protein microarray technology. Schematic resume of the main steps to 
perform an in situ protein microarray. A) printing of a DNA template and a capture agent; B) 
production of the proteins treating the slide with an IVTT mixture; C) capture of proteins from the 
capture agent; D) revealing of the protein of interest. 
 
 
2.7.1 PROTEIN IN SITU ARRAY (PISA)  
The PISA method (Fig. 18A) permits the generation of protein arrays in one step starting 
from PCR DNA fragments. In particular, these PCR fragments contain all the DNA sequence 
necessary for IVTT (T7 promoter, translation initiation site, poly(A)28 tail, transcription 
and translation terminators) and the protein cDNA fused with a double (His)6-tag 
sequence, which allows a stronger affinity binding to nickel ions (Ni2+) than standard 
(His)6-tag. In this way, the  generation of the DNA template doesn’t involve cloning 
passages, but different PCR cycles. As cell-free system a commercial kit based on rabbit 
reticulocytes lysate is currently used (T7 TnT Quick for PCR fragments).The template is 
added to the IVTT mixture and deposited on a Ni-NTA-coated microtiter plate or Ni-NTA 
magnetic agarose beads. After the reaction, the nascent protein is bound to the solid 
support thanks to the double (His)6-tag and can be subsequently analyzed. The authors 
tested the system using single-chain fragment variable (scFv) and experienced that in 25μl 
of reaction 120ng of protein was produced, of which 50% was bound on the microtiter 
[77]. 
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2.7.2 NUCLEIC ACID PROGRAMMABLE PROTEIN ARRAY (NAPPA) 
The Nucleic acid programmable protein array was designed by La Bear and colleagues in 
2004 [72] (Fig. 18B). In this method a plasmid DNA is cross-linked to psoralen-biotin 
conjugate through UV light and subsequently printed with avidin on a glass slide covered 
with aminopropyltriethoxysilane (APTES). The DNA template encodes the protein/peptide 
of interest, fused at the C-terminal to glutathione S-trasferase (GST)-tag. The presence of 
the GST-tag allows the capture of the nascent protein by a monoclonal anti-GST antibody 
spotted on the slide concurrently with the plasmid DNA. After the deposition of DNA and 
antibody, the slide is treated with IVTT system based on rabbit reticulocytes lysate and the 
protein, produced and captured, can be immediately analyzed. Instead of PISA, this method 
permits a high-density format thanks to the type of support used. Indeed it has been shown 
that 512 spots, spaced 900μm from each other, can be printed in a single slide and all the 
proteins are produced using only 100μl of IVTT reaction. Furthermore, they have 
demonstrated that 675pg of protein can be produced and capture in each spot. In 2008, the 
same group of researchers have improved the NAPPA technology by the use of an high 
quality super-coiled DNA and adding bovin serum albumin (BSA) to the printing solution 
[78]. Finally, in recent years, they have shown that an IVTT system based on HeLa cells led 
up to a major quantity of protein produced by printed DNA [79]. 
 
2.7.3 MULTIPLE SPOTTING TECHNIQUE (MIST) 
The multiple spotting technique is an high-throughput approach where a microarray slide 
is spotted a first time to allow the immobilization of proteins and a second time to permit 
the deposition of another compound, exactly in correspondence of the previous one [80]. 
Agenendt et al. have applied this method to build a new type of in situ protein array in 
which the first printing allows the spotting of DNA templates, plasmid or PCR fragments, 
and the second involves the deposition of the IVTT mixture [81] (Fig. 18C). After the 
expression, the proteins are immobilized on Nickel Chelate-coated or APTES slide and 
subsequently analyzed. The importance of this new approach is the limitation of protein 
diffusion and cross-talking, due to the deposition of the IVTT for every single spot. 
Furthermore, Angenendt et al. have demonstrated that only 35fg of unpurified PCR DNA 
are sufficient for the detection of full-length green fluorescent protein (GFP) in 
subnanolitre volume [81]. Moreover, the MIST allows to perform high-density protein 
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microarray with up to 13,000 spots in one slide. By now the MIST technology has not been 
used for particular studies, but its functionality is well characterized. 
 
2.7.4 TUS-TER ARRAY 
The most recent in situ protein array developed is the one called TUS-TER or Protein array 
on demand [74] (Fig. 18D). This method is based on the interaction between the E. coli 
protein TUS and a double stranded DNA sequence of 23bp called Ter. In vivo the binding of 
this protein to Ter allows the termination of the DNA replication. The peculiarities of this 
binding is that even if it is not covalent it is very strong (Kd= 3.4 x10-13) and it occurs only 
when the protein encounter this particular DNA sequence [82]. Chatterjee et al. have 
exploited the capability of this protein fusing it to cDNA of target proteins that can be 
immobilized from the Ter sequence [74]. In particular a plasmid DNA is used as template, 
because contains transcription and translation sequence and target protein-TUS cDNA, but 
also as capture agent because it contains the Ter sequence. After the DNA printing  on a 
nitrocellulose-coated slide, is only necessary to treat it with IVTT mixture to obtain the 
protein immobilization on the slide. The great advantage of this method is that there is no 
need for an additional molecule to capture the nascent protein, but only the presence of a 
plasmid DNA onto the microarray surface. To validate the system the Authors have also 
shown that the nascent proteins captured directly from the Ter site are present in the 
correspondent spot, therefore protein diffusion is avoided. 
 
2.7.5 DNA ARRAY TO PROTEIN ARRAY (DAPA) 
The DAPA methodology consists of the printing of a protein microarray using a DNA array 
as a mould [83] (Fig. 18E). In particular PCR fragments encoding for different proteins, 
fused to a tag, are spotted onto epoxysilane slide and subsequently the array is placed face 
to face with a second slide able to capture tagged proteins. Between the two slides a 
permeable membrane soaked with the IVTT mixture is present in order to allow the 
protein production. Afterwards, the proteins are produced starting from the DNA array, 
diffused through the membrane and are captured by the second slide. Using GFP as a 
control He and colleagues have evaluated that from 0,1ng of DNA template up to 30fmol of 
protein/spot can be captured. The great innovation of this technology is the possibility to 
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reuse the same DNA array to produce many protein arrays. It has been demonstrated that a 
single DNA array can be reused almost 20 times without significant variation [84]. Finally, 
it has been demonstrated that scFvs can be spotted on a slide using DAPA and they are also 
functional. These results are promising for the utilization of DAPA technology in proteome 
studies. 
 
2.7.6 IN SITU PUROMICYN-CAPTURE FROM mRNA ARRAY  
This type of microarray is the only one using RNA as a template. It is based on the 
assumption that when a ribosome encounters a region of double-stranded RNA or DNA-
RNA hybrid it is not immediately released but it stalls on the mRNA. Tao and Zhu have 
hypothesized that this ribosome stalling can be long enough to provide the incorporation of 
a puromycin-grafted oligo immobilized on a solid phase, therefore the nascent polypeptide 
is directly captured by the puromycin [76] (Fig. 18F). This strategy consists of the 
immobilization, on a streptavidin-coated slide, of biotinylated puromycin-oligo and mRNA, 
which anneals at a 3’ end to an RNA bumper oligo, so as to form a double-stranded RNA. 
After printing, the slide is treated with an in vitro translation mixture based on rabbit 
reticulocytes lysate and after the synthesis, the nascent peptide is captured by the 
puromycin-oligo. Finally, the slide is treated with a solution containing RNAse that 
degrades the mRNA, in order to have on the slide only the newly synthesized protein. After 
the assessment of the technology, the Authors have evaluated that, using this approach, 0,8 
fmol/spot of protein are captured on the slide surface and this results are comparable with 
those of traditional protein microarray. 
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Figure 18. Schematic representation of all in situ protein microarrays. A) PISA: protein in situ 
array; B) NAPPA: nucleic acid programmable protein array; C) MIST: multiple spotting technique; 
D) TUS-TER array; E) DAPA: DNA array to protein array; F) in situ puromycin-capture from mRNA 
array. 
 
2.7.7 IN SITU PROTEIN ARRAY APPLICATIONS 
The main application of in situ protein microarrays is the individuation of protein-protein 
interactions. All the types of in situ protein array, previously described, can be used for 
interaction studies [55; 72; 74; 75]. In particular the NAPPA methodology is a great tool for 
this type of application due to the possibility of producing at same time query and target 
protein. La Bear et al. have demonstrated this capability using the Cdk inbhitor p16 as a 
query protein and Cdk4 and Cdk6 as positive targets, whereas Cdk2 has been used as 
negative control [72]. Furthermore, new protein-protein interactions were discovered 
thanks to in situ protein arrays [72; 85]. Besides interaction studies, the in situ protein 
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arrays which have been used for other kind of applications are NAPPA and PISA methods. 
The NAPPA was used in immunogenicity and immunoprofiling studies. In 2009, Montor et 
al., have directed a genome-wide study on Pseudomonas aeruginosa outer membrane 
proteins immunogenicity. According to this method, the reactivity of patients sera, positive 
or negative to cystic fibrosis, infected with P. aeruginosa, to bacteria outer membrane 
proteins was analyzed [86]. In this study the Authors identified a total of 48 antigens, 12 of 
which  were detected in 10 patients and were considered as promising candidate for in-
depth studies. Other similar studies were performed on different organisms, like 
Ornithodoros moubata [87], Plasmodium falciparum [88]and Coxiella burnetii [89], 
confirming that NAPPA is an important tool for immunogenicity studies and vaccine 
development. Moreover, NAPPA can also be considered suitable for immunoprofiling, since 
two different studies, in which this technology was used to analyze possible autoantibody 
biomarkers for early breast cancer and juvenile arthritis, were published [90; 91]. The 
usage of this novel methodology demonstrated that is possible to identify autoantibody 
biomarkers that is important not only for the diagnosis and the follow-up of the disease, 
but also to determine disease stages. In the matter of PISA method has been published the 
possibility to perform screening studies, functional assay and identification of mutants 
[92]. 
 
2.7.8 IMPROVEMENTS AND FUTURE PROSPECTIVES 
In situ protein arrays have demonstrated to be a great tool for proteome studies and they 
have overcame the main drawbacks related to standard protein arrays. Under this aspect, 
many improvements regarding protein production, sensitivity and cross-talk were done in 
recent years. In 2010 a group of researchers have demonstrated that combining E. coli with 
wheat germ IVTT lysate, a major quantity of functional protein can be produced and 
captured on a glass slide, compared to rabbit reticulocytes lysate, that is the most IVTT 
used in in situ array technology [93]. Furthermore, based on NAPPA technology, these 
Authors have developed an autofluorescent microarray where the target protein is fused to 
a GFP, instead of GST-tag, and the nascent protein is captured by anti-GFP monoclonal 
antibody. With this approach, the protein is revealed immediately after the production, 
without the need of other treatments. Another important improvement of in situ protein 
arrays regards protein diffusion during the IVTT reaction that can cause cross-talking 
 36 
between different spots. In a standard NAPPA slide the distance between two spot is 
625μm that means approximately 2000 proteins analyzed on a single slide. This spot to 
spot space is the minimum distance necessary to avoid cross-talking events using NAPPA 
technology. To increase the density of NAPPA slide, without the presence of protein 
diffusion, a new type of slide was set up [94]. This slide is made of silicon and is composed 
of semispherical nanowells of 250μm in diameter, 75μm in depth and distanced each other 
375μm. These nanowells are produced with photolithography and can be subsequently 
functionalized with different chemical groups. Moreover, every nanowell can contain 5nl of 
IVTT reaction mix indicating a minimal consume of cell-free IVTT systems that are 
expensive tools. The last challenge of in situ protein arrays is the use of label-based 
methods that are limiting and less sensitive, instead of label-free methods. For this reason, 
many groups have tried to combine this new type of arrays with label-free methods. Two 
different groups have demonstrated the possibility of combining NAPPA or MIST to matrix-
assisted laser desorption/ionization (MALDI)[95; 96]. Furthermore, in 2012, an on-chip 
microfluidic protein microarray based on NAPPA technology was developed [97]. This 
method consists in a generator element where a dsDNA encoding for His6 tagged proteins 
and a detector element composed by a Cu(II)-NTA group are immobilized. When the 
microfluidic chip is treated with the IVTT mixture, the protein is produced from the DNA 
template and directly absorbed by the detector element and can be immediately used in 
surface plasmon resonance imaging (SPRI). Finally, the possibility to combine NAPPA 
methodology with other label-free methods like: nanogravimetry, atomic force microscope 
and anodic porous alumina, has been reported (APA)[98]. Thanks to all these 
improvements, in situ protein arrays are increasingly becoming a new technology able to 
analyze thousands of elements in almost one day and suitable for many other purposes.  
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3. AIM OF THE PROJECT 
 
As described in the introduction, antibodies have become an important tool not only in 
scientific research, but also in proteome discovery, diagnosis and therapy. For this purpose, 
several improvements have been done in antibody production, selection and validation 
[23], but many proteins still remain unknown and without antibodies able to recognize and 
identify them. Moreover, many commercial antibodies present cross-reactivity or less 
specificity against their target [10; 11]. This leads to a not specific antibodies validation. It 
is became clear that an antibody has to be validated in relation with the experimental 
needs, but it can results laborious and cost-time expensive. For this reason the aim of this 
project is to develop new high-throughput technologies for antibodies validation. My 
laboratory has take part in a National Institute of Health (NIH) project, coordinated by 
Andrew Bradbury (National Laboratories of Los Alamos), that has the aim to produce, with 
high-throughput technologies, specific polyclonal antibodies against hundreds different 
proteins. In particular the project consists of (Fig. 19): 
1. production of the target proteins; 
2. selection of polyclonal antibodies through a phage/yeast display combination [43]; 
3. validation of the polyclonal antibodies with Western blot, ELISA and protein 
microarray; 
4. set up of a new platform for high-throughput antibodies validation: protein array on 
demand. 
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Figure 19. Experimental scheme of the project.  The project consists of four different parts: 1. 
Protein production (antigens); 2. Selection of polyclonal antibodies against the putative antigens; 3. 
Validation of antibodies with WB, ELISA and protein microarray; 4. High-throughput antibodies 
validation using “protein array on demand”. 
 
The first part of the project (proteins production and antibodies selection) has been carried 
out in collaboration with Los Alamos Laboratories. After the scFvs selection, through 
phage/yeast display combination, and scFv-Fc rabbit polyclonals production in yeast cells, 
the polyclonals were sent us for validation with WB, ELISA and standard protein array. 
Subsequently, since protein microarray has some drawbacks, such as intensive protein 
production and immobilized proteins functionality, we want to set up an high-throughput 
protein array suitable for antibody validation. In particular, an in situ protein array called 
“protein array on demand” has been chosen for this purpose. 
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5. MATERIALS AND METHODS 
 
Materials. As microarray slides FAST (Whatman) and Codelink® activated (Surmodics) 
were used. In ELISA, Western blot and protein microarray analysis the subsequent 
antibodies were employed: anti-SV5 (in house made), anti-mouse IgG horseradish 
peroxidase (HRP) conjugated (Dako), anti-mouse IgG alkalin phosphatase (AP) conjugated 
(Sigma), anti-mouse IgG Cyanine3 (Cy3) conjugated (Listarfish), anti-rabbit IgG HRP 
conjugated (Sigma), anti-rabbit IgG Cyanine5 (Cy5) conjugated (Listarfish) and polyclonal 
rabbit anti-CDK2A (full-length protein) (Santa Cruz). To reveal biotinylated proteins 
streptavidin HRP conjugated (BIOSPA), streptavidin AP conjugated (Sigma) and 
streptavidin phycoerythrin (PE) conjugated (Life Technologies) were used. As AP and HRP 
developer the nitro blue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate 
(NBT/BCIP) (Roche) and 3,3’,5,5’-Tetramethylbenzidine (TMB) (Sigma) were used. All PCR 
reactions were performed with GoTaq Flexi (Promega). In vitro transcription and 
translation kit used are: T7 TnT quick coupled transcription and translation system 
(Promega), T7 TnT quick for PCR DNA coupled transcription and translation system 
(Promega), TnT coupled Wheat Germ extract System (Promega) and 1-Step Human 
coupled in vitro expression kit (Pierce). Bacteria strains used: DH5α and NM522. 
Additional compounds: streptavidin (Biospa), bovine serum albumin (BSA) (Sigma), triton-
X 100 (Sigma), tween-20 (Sigma), ampicillin (Sigma), 2xTY media (Sigma), select agar 
(Sigma), agarose (Sigma), TEMED and APS (Sigma), Page ruler Plus Protein marker 
(Fermentas), Quant-it™ PicoGreen® (Life Technologies).  
 
Buffers and solutions. Codelink print buffer 6x (300mM sodium phosphate, pH 8.5), 
Codelink saturation buffer (10mM Tris-Hcl, 50mM ethanolamine, pH 9), phosphate 
buffered saline (PBS) (NaCl 0.137M, Na2HPO4 4,3mM, KCl 2,7mM, KH2PO4 1,5mM), TE 
buffer (Tris 10mM, EDTA 1mM pH 7.4), sample buffer 2x (Tris-HCl pH6,8 125mM, SDS 4%, 
glycerol 20%, β-mercaptoethanol 10%, blue bromophenol 0,004%), coomassie staining 
(acetic acid 10%, methanol 45%, coomassie blue R-250 0,1%), coomassie destaining 
(acetic acid 10%, methanol 10%). 
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Western blot antibodies validation. Biotinylated proteins were denaturated with SB 2x 
and loaded on a polyacrylamide gel for SDS-PAGE. After gel transfer, the nitrocellulose 
membrane was saturated in 4% milk in PBS plus tween-20 0,01% (PBST) for 1 hour at 
room temperature. The nitrocellulose was treated with polyclonal supernatants at 1:5 
dilution in 2% milk in PBST and subsequently with anti-rabbit IgG-AP at 1:5000 in the 
same buffer. The membrane has been developed with NBT BCIP. 
 
Sanger sequencing. PCR fragments were quantified by agarose gel and a sequencing 
reaction was carried out with: primer at 3,2μM concentration, 1μl of Big Dye Terminator 
(Applied Biosystems) mix and distillated water till 10μl final volume. The amount of DNA 
used depends on its length, according with the Big Dye datasheet. Susequently, the 
sequences reaction was purification on columns containing sephadex resin (Princeton 
Separation). After resin hydratation with 800μl of water, two centrifugation at 3600 rpm 
for 2’ were carried out, to completely eliminate the water. The sequencing reaction was 
loaded on the resin and another centrifugation was performed, on order to eluate the 
purified reaction. This was mixed with formammide, denaturated for 2’ at 96°C and 
analyzed with ABI 3130xl Genetic Analyzer. 
 
Antibodies validation with ELISA. Yeast supernatants, produced by National Laboratories 
of Los Alamos, containing rabbit polyclonal antibodies were validated using ELISA test. The 
corresponding proteins were coated on 96 well plate, at 10ng/μl in PBS and stored at 4°C 
overnight. The saturation was carried out with 2% milk in PBS and supernatants were used 
at 1:5 dilution in saturation buffer. The antibodies were revealed with anti-rabbit IgG-HRP 
at 1:5000. To verify the antigen coating a streptavidin-HRP at 1:200 were used.  
 
Antibodies validation with protein microarray. All the biotinylated proteins, sent us from 
the Los Alamos National Laboratories, were brought to 50ng/μl concentration and put in a 
384 well plate for microarray printing. The proteins were print on FAST slide, at 15°C and 
50% humidity using the Biodeassay Calligrapher (BioRad). When printing finished, the 
slide was stored overnight at room temperature in a less humidity chamber. The day after, 
it was saturated with 4% milk in PBST at room temperature, with shacking, for 1 hour. 
Subsequently, the slide was  treated with polyclonal supernatants at 1:5 dilution in 2% 
milk PBST for 1hour at room temperature. As secondary antibody an anti-rabbit IgG-Cy5, at 
1:200 dilution, was utilized. To verify the protein spotting a streptavidin-PE, at 1:400 
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dilution, was used. To read the spots fluorescence and quantify them a ScanArray Gx 
(Perkin Elmer) was employed. 
 
Protein array on demand vector design. A commercial plasmid optimized for cell-free 
expression in eukaryotic systems, called pTNT™ (Promega)(Fig. 20A), was used as template 
for rabbit reticulocytes lysate and wheat germ IVTT kits. The original Multiple Cloning Site 
(MCS) of pTNT™ was substituted with a new ones containing (Fig. 20B):  
1. BssHII and NheI as restriction site for proteins of interest (POIs) insertion; 
2. SV5 tag; 
3. TUS protein cDNA with the E47Q mutation; 
4. His6 tag. 
This new MCS was created through three different PCR cycles to obtain a DNA sequence 
that cuold be subsequently cloned in pTNT™, using XhoI and XbaI as cloning sites (Fig. 
20B). The three PCR cycles were carried out with the following primers:  
- TUS sense-1 (5’-TGCCGCTCATCTTGAGCAACACAAGCTATTGGTTGCCCGCGTGTTCTCT 
TTGCCGGAGTAAAAAACAGGATGAGCATAATCCGC-3’),  
- TUS sense-2 (5’-GATGCGCGTTACGATCTCGTAGACCGACTCAACACTACCTTTCGCCAGA 
TGGAACAAGAGCTGGCTATATTTGCCGCTCATCTTGAGCA-3’);  
- TUS sense-3 (5’-ACGTCTCGAGCCACCATGGGCGCGCATGCCAGGCTAGCGGCAAACCAA 
TCCCAAACCCACTGCTGGGCCTGGATGCGCGTTACGATCTC-3’)  
- TUS anti (5’-ACGTTCTAGAACTTAATGATGGTGATGATGGTGATCTGCAACATACAGGT 
GCAGCCGTGG-3’).  
The new vector obtained will be called pTNT-TUS. All the proteins of interest were cloned 
using BssHII and NheI restriction sites. 
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Figure 20. pTNT™ vector maps and Multiple Cloning Site. pTNT™ vector optimized for cell-free 
expression in eukaryotic  lysate. A) pTNT™ vector map  and MCS containing: ampicillin resistance, 
T7 and SP6 promoter, poly(A)30 tail  and T7 terminator. B) pTNT-TUS MCS. 
 
 
Cell-free protein production. To allow the expression with HeLa cells IVTT system an 
encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES) sequence was 
inserted in the pTNT-TUS vector. This sequence is essential for an efficient cell-free 
protein expression with lysate based on HeLa cells. The IRES was introduced in the pTNT-
TUS vector through subcloning from pT7CFE1-His plasmid (Thermo Scientific), supplied 
with HeLa IVTT kit. The IRES sequence was amplified with a PCR reaction using the 
following primers: 
- IRES XhoI sense: (AGCTCTCGAGGGTTATTTTCCACCATATTGCCG); 
- IRES BSSHII anti: (AGCTGCGCGCCCATATTATCATCGTGTTTTTCAAAGG). 
Ampr 
PolyA30 Tail 
T7 Terminator 
f1 ori 
ori 
BamHI 
208 
BglII 
2866 pTNT™ 
(2,871bp) 
pTNT™ Multiple Cloning Site 
A) 
B) 
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The amplified DNA was cut with XhoI and BssHII restriction enzymes and cloned in pTNT-
TUS vector. This new plasmid will be called pIRES-TUS.  All these plasmids were used with 
the corresponding IVTT lysate and the reaction was carried out following the kits data 
sheet (Tab. 1). 
 
IVVT Lysate Rabbit reticulocytes 
(RRL) 
Wheat germ (WG) HeLa 
Compounds 
(50μl reaction) 
 Master Mix 40μl 
 Methionine 1μl 
 Water till 50μl 
  Extract 25 μl 
  Reaction buffer 2 μl 
  RNA Polymerase 1 μl 
  AA minus Met 1μl 
  AA minus Leu 1μl 
  Water till 50μl 
  Lysate 15μl 
  Accessory protein 5μl 
  Reaction Mix 10μl 
  Water till 50μl 
DNA (ng) 1000 1000 1000 
Time and 
Temperature 
1h30’ at 30°C 1h30’ at 30°C From 90’ to 6h at 30°C 
 
Table 1. IVTT reaction kit data sheets. Description of the IVTT compounds, time and 
temperature needed for all the  kits used. 
 
All the kits could be used for protein expression starting from PCR fragments, but in case of 
IVTT based on rabbit reticulocytes lysate it was employed a kit optimized for PCR 
templates. The reaction compounds, time and temperature were the same of IVTT based on 
RRL plasmid kit. After the expression the proteins were loaded on polyacrylamide gel for 
Western blot analysis using the anti-SV5 at 1:5000. 
 
TUS fusion protein binding to Ter sequence. The streptavidin at 10ng/μl was coated on 
384 wells low volume plate (CORNING) at 4°C overnight. The day after the wells were 
washed briefly with PBS and subsequently incubated with 1000ng of 5’-biotinylated PCR 
obtained with primers pTNT seq bio (5’-bio- ACGGTTCCTGGCCTTTTGC-3’) and pTNT anti 
or pTNT anti Ter (5’- CACTTTAGTTACAACAT ACTTATTAGGGAAGGGCGATCGGTG-3’), in 
which pTNT-TUS plasmid was the template. After 1h incubation, the DNA was discarded 
and the saturation with 2%milk in PBS was carried out. Subsequently, 10μl of the IVTT mix, 
already performed in vials, was added to the wells and incubated for 1h. After three 10’ 
PBST washes, the anti-SV5 1:5000 was utilized to protein binding revealing. As secondary 
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antibody an anti-mouse IgG-HRP was used. All the incubation were performed at 30°C. The 
ELISA was read at 450nm with a Plate Reader. 
 
Protein Array on demand. Biotinylated PCRs DNA at 400ng/μl were spotted on CodeLink 
activated slides. After the spotting, slides were incubated in a humidity chamber salt 
saturated overnight for covalent binding achievement. The day after, slides were saturated 
with CodeLink saturation buffer for 45’ at room temperature and washed quickly with 
distillated water. Subsequently, for every 16 well PAD, 60μl of IVTT mix were deposited on 
the slides and incubated at temperature and time according to the IVTT kit used. After 
protein expression the slides were incubated at 15°C for 30’ for TUS-Ter binding 
stabilization. After 15’ PBST wash, the anti-SV5 at 1:5000 in PBS was used. Three 10’ PBST 
washes were carried out before anti-mouse IgG-Cy3 at 1:200 in PBS addition. The 
previously washes were repeated and additional quickly washes with PBS and water were 
performed before slide drying. To control dsDNA printing the PicoGreen at 1:200 in TE 
buffer was used. Spot signals were read with the ScanArray Gx. 
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5. RESULTS 
 
5.1 CHARACTERIZATION AND VALIDATION OF RABBIT POLYCLONAL 
ANTIBODIES 
 
The first aim of the project was to select, with a phage/yeast display combination, scFvs 
produce them as scFv-Fc rabbit polyclonals, in yeast cells, and validate their specificity 
using Western blot, ELISA and protein microarray. In collaboration with the Los Alamos 
National Laboratories 78 different proteins were selected, for solubility and molecular 
structure, as target antigens of the NIH project (data not shown). All these proteins were 
produced as biotinylated proteins in E. coli and tested with Coomassie staining and 
Western blot analysis, carried out with streptavidin-AP staining (Fig. 21). 
 
Figure 21. Putative antigens production. 78 proteins were produced as biotinylated proteins. 
One microlitre of each protein was loaded on a polyacrylamide gel and a Coomassie staining (left 
panel) and Western blot analysis(right panel) were carried out. The Western blot were performed 
with a streptavidin-AP 1:3000. Only 22 proteins are reported in this figure. 
 
All proteins tested showed a good production yield using E. coli cells and were all soluble. 
Furthermore, all proteins were full-length and linked to the biotin. To evaluate the 
polyclonal antibodies selection protocol, only the first seven antigens of the list were 
selected to be used for the selection and production of polyclonal antibodies (Tab. 2).  
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PROTEINS (TOP 7) ABBREVIATION MOLECULAR 
WEIGHT (kDa) 
LENGTH 
(bp) 
Cyclin-dependent kinase 2 A CDK2A 38,5 894 
C-terminal binding protein 2a CTBP2A 41,7 1005 
MAP kinase 2A5 MAPK2A5 16,4 315 
MAP kinase 8B MAPK8B 46,4 1089 
Phospholipase A2 activating protein PLAA 54,6 1374 
Splicing factor 3A subunit 1 SF3A1 40,9 954 
Ubiquitin specific peptidase 11 USP11 30,4 675 
 
Table 2. TOP 7 antigens. List of the first seven proteins chose for the first round of polyclonal 
antibodies selection. 
 
The strategy used was the following (Fig. 22): 
1. a scFvs library [99] was cloned in a phagemid vector (pDAN) and two rounds of phage 
display selection were performed; 
2. the enriched scFvs library was subsequently subcloned, with homologous 
recombination, in a yeast display vector, that used the a-agglutinin system for scFvs 
display. Two rounds of sorting with FACS were performed; 
3. the selected scFvs were cloned, with homologous recombination, in a yeast expression 
vector to allow the production of scFv-Fc with a rabbit Fc.  
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Figure 22. Polyclonal selection and production strategy. The strategy to select highly specific 
polyclonal antibodies consists of: 1. scFvs library cloning in a phage display vector and scFvs 
selection with two rounds of selection; 2. enriched scFvs library cloning in a yeast display vector 
and two rounds of selection with FACS analysis; 3. expression of the selected scFvs using yeast cells 
to obtain scFv-Fc polyclonal antibodies where the Fc is composed by rabbit IgG CH2-CH3. 
 
The scFv-Fc polyclonal antibodies were sent us as yeast cells supernatants for the 
validation analysis with: Western blot, ELISA, protein microarray. From the Los Alamos 
National Laboratory we received:  
1. 78 antigens DNA in form of plasmid vector; 
2. 78 biotinylated antigens.  
3. polyclonal antibodies DNA in form of plasmid vector; 
4. yeast supernatants containing the polyclonal antibodies; 
 
 
 
CH2 
CH3 
CH2 
CH3 
 48 
5.1.1 Western blot and ELISA polyclonal antibodies validation 
After receiving all the samples from Los Alamos, the TOP 7 antigens were tested. To verify 
the grade of degradation and the protein concentration a Coomassie staining was 
performed (Fig. 23A). On the other hand, the proteins biotinylation were controlled with 
Western blot analysis using streptavidin-AP (Fig. 23A).  
 
 
 
 
 
 
 
 
    
Figure 23 . TOP 7 antigens concentration and biotinylation test. The seven antigens sent us 
from Los Alamos National Institute were loaded on polyacrylamide gel to perform a Coomassie 
staining and a Western blot analysis. A) One microlitre of proteins was loaded in the following 
order: a) CDK2A; b) CTBP2A; c) MAPK2A5; d) MAPK8B; e) PLAA; f) USP11; g) SF3A1. To allow the 
protein quantification on the Coomassie gel a BSA calibration curve (250ng, 500ng, 750ng, 1000ng, 
2000ng) was used. The Western blot was developed using a streptavidin-AP diluted 1:3000. B) 
Proteins were quantified by Imagej software; the BSA calibration curve was used as reference to 
construct a tendency line. The correspondent equation were used for proteins concentration 
calculation.  
 
MW a b c d e f g MW a b c d e f g BSA  
17 
28 
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A) 
B) 
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The Western blot analysis showed that all the proteins were full-length and biotinylated. 
Instead, in the Coomassie staining could be observed that the degradation was limited for 
all proteins tested. Furthermore, the Coomassie gel was used to estimate the protein 
concentration using the BSA calibration curve as reference. The signal intensity of bands 
was quantified by the ImageJ software and used to calculate the concentration of each 
protein (Fig. 23B). After antigen integrity and biotinylation evaluation, the yeast 
supernatants validation were performed initially with Western blot and ELISA analysis. In 
the first experiment, the polyclonals ability to recognize their specific antigens, in a 
denaturated form, compared to a control protein, were verified. Biotinylated antigens and 
the control protein (BSA) were loaded on a polyacrylamide gel and transferred on 
nitrocellulose membrane. Every polyclonal was tested on the correspondent antigen and 
the control protein (Fig. 24). All the yeast supernatants were used at 1:5 dilution and an 
anti-rabbit IgG-AP were used as secondary antibody, to allow the Western blot 
development.  
                       
Figure 24. Western blot validation. The TOP7 antigens (400ng) were loaded on a polyacrylamide 
gel and transferred on a nitrocellulose membrane. Every protein (A3: CDK2A; A7: CTBP2A; A10: 
MAPK2A5; B5: MAPK8B; C11: PLAA; D2: SF3A1; D4: USP11) and a supplemented control protein 
(BSA) was treated with the correspondent yeast supernatant at 1:5 dilution. The anti-rabbit-AP 
1:5000 was used for antibodies staining revealing.  
 
From these Western blots it could be concluded that five polyclonal antibodies (anti-
CDK2A, anti-MAPK2A5, anti-PLAA, anti-USP11, anti-SF3A1) were able to recognize the 
target in a denaturated form. On the other hand, only two supernatants didn’t work in 
Western blot. This suggested that these two selected polyclonals could identify only 
conformational epitopes. Another hypothesis was that the yeast supernatant components 
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could interfered with the antigen recognition. An interesting aspect was that all the 
antibodies didn’t show cross-reaction to the control protein, confirming high specificity of 
the selection protocol. After this preliminary results, a second validation test were 
performed using ELISA. In this analysis the yeast polyclonal supernatants were tested with 
all the seven biotinylated proteins, simultaneously, to control their specificity. The TOP7 
antigens were coated on a 96 wells plate at 10ng/μl in PBS, at 4°C overnight. All the seven 
polyclonals were used at 1:5 dilution for ELISA development (Fig. 25A).  
 
 
 
 
 
 
 
 
Figure 25. ELISA polyclonal antibodies validation. The seven antigens were coated at 10ng/μl 
concentration on ELISA plate. As primary antibody the yeast supernatants, at 1:5 dilution, were 
used. The proteins revealing was carried out with an anti-rabbit IgG-HRP. The values were read at 
an optical density of 450nm with a plate reader. 
 
From these experiments could be observed that all the polyclonal supernatants were able 
to recognize specifically their own antigen. Furthermore, none of the antibodies showed 
cross-reactivity to the other proteins, confirming their high specificity. Despite that, the 
anti-SF3A1 and anti-MAPK8B polyclonals gave lower signals than the others. This problem 
could be related to a lower antibodies concentration in the yeast supernatant. In order to 
confirm this hypothesis antibodies concentration was measured by a second ELISA, with 
yeast supernatants coated directly on plate and developed with an anti-rabbit IgG-HRP 
(Fig. 26). In this way, it was possible to compare the amount of antibodies in the different 
supernatants.  
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Figure 26. Antibodies concentration in yeast supernatants. Yeast supernatants, containing the 
polyclonal antibodies, were coated on ELISA plate at 1:10 dilution and developed with anti-rabbit 
IgG-HRP at 1:5000 dilution. The values were read at 450nm with a plate reader. 
 
As previously supposed, the amount of antibodies in the anti-SF3A and anti-MAPK8B was 
lower than the other polyclonal supernatants. In conclusion, the anti-SF3A and anti-
MAPK8B supernatants contained a low amount of antibodies that caused low signals in the 
ELISA validation.  
 
5.1.2 Protein microarray optimization 
The Western blot and the ELISA validations have shown that all the polyclonals could 
identify their target protein in the conformational state and only two of them couldn’t 
recognize the antigen in a denaturated form. Furthermore, the seven antibodies didn’t 
reveal cross-reactivity to the other six targets, confirming their high specificity. As showed 
in the introduction these two validation are not sufficient for a good antibody validation 
test. For this reason, another technology, able to validate the antibodies on a largest scale, 
were used. This technology is the protein microarray. The polyclonal supernatants were 
tested on the 78 antigens listed at the beginning of the project, already produced as 
biotinylated proteins. First, a way to standardize the amount of protein spotted was 
needed. All the biotinylated antigens were spotted at 50ng/μl and, after saturation, treated 
with streptavidin-PE (Fig. 27A). As negative controls six non biotinylated proteins, 
available in our laboratory, were used. In Figure 27 it is shown the optimized protein 
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spotting that will be used in all subsequent protein arrays. The scan images were also 
quantified and the values are reported in a graph (Fig. 27B).  
 
  
                
 
 
 
 
Figure 27. Protein microarray standardization. The 78 biotinylated antigens were spotted in 
duplicate, at 50ng/μl in PBS, on FAST slide. Other six random no biotinylated proteins were spotted 
as negative controls. A) Print scheme: biotinylated (red)and not biotinylated (white) proteins. After 
incubation with streptavidin-PE, the array was scanned with the ScanArrayGx. B) The spots 
intensity were calculated as media of the numbers of pixel minus background pixels by 
ScanArrayGx. For every proteins a media of the duplicates were calculated and reported in the 
graph. C) Box-plot of the quantified bio-proteins spots intensity.  
 
As it could be observed in the array scan as well as in the histogram, although the level 
should be the same for all the proteins some were presented at a much lower 
concentration than expected. This could be due either to protein degradation, during 
storage, or to lower protein stability, when immobilized on the array slide. The distribution 
analysis, performed with a box-plot (Fig. 27C), revealed that the major part of the proteins 
was collected in the same intensity range, 35000 to 50000. Nevertheless, excluding the 
lower concentrated proteins, the majority of the spots intensities were comparable 
between each other and high enough for being detected with a specific antibody. To 
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perform a good protein array is also necessary to normalize the signals. Since that the 
protein array will be used to validate rabbit polyclonal antibodies, a rabbit IgGs calibration 
curve was used in the normalization. Rabbit IgGs were spotted at different concentrations 
on FAST slide and treated with the anti-rabbit IgG-Cy5 (Fig. 28). The array was scanned 
and quantified (Fig. 28). 
 
                     
   
 
Figure 28. Rabbit IgGs calibration curve. To allow the polyclonal antibodies signals 
normalization a rabbit IgGs calibration curve was set up. Different concentrations of rabbit IgGs 
were spotted in duplicates and treated with anti-rabbit IgG-Cy5. In the left panel was shown the 
array scan with the correspondent IgGs concentrations. The quantification of these spots was 
reported in the graph (right panel) and a tendency line was designed. The values read by ScanArray 
Gx represent the media-background spots pixels. The media of the duplicates was calculated and 
put in the graph. 
 
The IgGs calibration showed that the first two points of the curve (15μg/ml and 10μg/ml) 
corresponded to the saturation signal, demonstrating that 10μg/ml could be considered as 
the saturation point. Furthermore, from the graph could be observed that the IgGs 
tendency line was linear and with the R2 value = 0,962. This analysis confirmed that this 
rabbit IgGs calibration curve could be used for all the further antibody validation by 
microarray. 
 
5.1.3 Protein array validation of yeast polyclonal supernatants 
Protein microarrays were set up and optimized for the polyclonal antibodies supernatants 
validation. The 78 biotinylated antigens and the rabbit IgGs calibration curve were spotted 
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as previously described. After overnight dehumidification, the slide was saturated and 
subsequently treated with yeast supernatants at 1:5 dilution (Fig. 29). As positive control a 
streptavidin-PE was utilized. 
                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Yeast supernatants validation with protein array. The 78 antigens were spotted in 
duplicates on FAST slide at 50ng/μl. A rabbit IgGs calibrator (15μg/ml, 10μg/ml, 5μg/ml, 2μg/ml, 
1μg/ml, 0,2μg/ml) was also printed. In the print scheme the TOP7 antigens are indicated as: a 
(CDK2A), b (CTBP2A), c (MAPK2A5), d (MAPK8B), e (PLAA), f (SF3A1) and g (USP11); whereas the 
rabbit IgGs are depicted in blue. A positive control with streptavidin-PE is shown in the top right 
panel. The other PADs were treated with all the different yeast supernatants at 1:5 dilution. The 
slide was scanned with the ScanArray Gx. For every scan the correspondent antigen is highlighted 
with a red rectangle. 
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The protein array validation (Fig. 29) showed that three polyclonal supernatants (anti-
CDK2A, anti-MAPK2A5, anti-USP11) worked very well. They could recognized specifically 
their own target without showing cross-reactivity to the other proteins. The anti-PLAA and 
anti-SF3A supernatants were also able to recognize the specific target, but were less 
sensitive than the previous three. In case of anti-SF3A polyclonal, the problem could be 
related to the low antibody concentration in the supernatants shown in ELISA (Fig. 26). In 
the other case, the lower sensitivity of the anti-PLAA could be related to the presence of the 
yeast supernatant components, that could interfered with the antibody-antigen binding. 
Finally, the anti-MAPK8B and anti-CTBP2A seem to be unable to identify the target 
proteins. In case of anti-MAPK8B, analyzing the array with an higher laser power 
(excluding the rabbit IgGs calibration curve to avoid saturation) it was possible to get 
positive spots correspondent to the target protein (Fig. 30). This confirmed that anti-
MAPK8B supernatant was functional and specific but gave a low signal out of the IgGs 
calibration curve. The array treated with the anti-CTBP2A resulted negative even if the 
IgGs curve was excluded (Fig. 30). Since that this supernatant worked in ELISA but not in 
Western blot, the problem in microarray analysis could be related to the degradation of the 
CTBP2A once spotted on the slide.  
 
                                                  
 
 
 
 
Figure 30. Array Scan without rabbit IgGs calibration curve. The PADs correspondent to anti-
CTBP2A (b) and anti-MAPK8B (d) were re-scanned excluding the IgGs calibration curve.  
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5.1.4 Protein microarray validation of purified polyclonal scFv-Fc 
From the previous protein array analysis arose that only three polyclonal supernatants 
were specific and sensitive to their target. The other polyclonals were resulted specific but 
with a lower sensitivity. One of the hypothesis, linked to this low sensitivity, was related to 
the antibodies concentration in the yeast supernatants. Indeed, the seven polyclonals 
presented different antibodies concentration that can leaded to different signals, 
independent to the antibody avidity. The other idea was related to the presence of the 
yeast supernatants components that could, in some cases, masked the antibody-antigen 
binding. For these reason the polyclonal supernatants were purified in order to obtain 
scFv-Fc polyclonals. These purified antibodies were sent us and tested with a new protein 
array (Fig. 31). All the purified polyclonal antibodies were used at 1ng/μl.  
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Figure 31. Purified polyclonal antibodies validation with protein array. The 78 antigens were 
spotted in duplicates at 50ng/μl. A rabbit IgGs calibration curve was printed for signal 
normalization (15μg/ml, 10μg/ml, 5μg/ml, 2μg/ml, 1μg/ml). In the print scheme are shown the 
TOP7 antigens position (a (CDK2A), b (CTBP2A), c (MAPK2A5), d (MAPK8B), e (PLAA), f (SF3A1), g 
(USP11)), the rabbit IgGs (bleu) and an empty spot (black). As positive control a streptavidin-PE 
was used. The other PADs of the same array were treated with 1ng/μl of purified polyclonal 
antibodies. The array scans were performed with ScanArray Gx. For every PAD the correspondent 
antigen is highlighted with a red rectangle. 
 
In this new validation experiment it could be immediately noted that purified antibodies 
worked better that the not purified yeast supernatants. The three antibodies already 
positive as supernatants (anti-CDK2A, anti-MAPK2A5, anti-USP11), showed the same 
signals in the purified form. The anti-SF3A1 and anti-PLAA polyclonal, that in the previous 
validation were able to recognize their antigens with low sensitivity, in this case showed an 
enhanced specificity and sensitivity. As expected from previous results, all these five 
polyclonals didn’t show a cross-reactivity to all the other proteins spotted on the slide. 
These results demonstrated that using the same amount of antibodies an higher signal can 
be achieved. Furthermore, the absence of the supernatant components might increase the 
antibody-antigen binding. The last two polyclonal antibodies (anti-CTBP2A, anti-MAPK8B) 
confirmed the low performance when used as purified as in supernatants. The purified 
anti-CTBP2A polyclonal was able to recognize its specific target, but reacted also to another 
protein: MAPK2A5. The purified anti-MAPK8B polyclonal didn’t show any reactivity to its 
target protein and to the others. Even if the IgGs calibration curve was excluded from the 
scan the anti-MAPK8B resulted negative (data not show). In conclusion, five polyclonal 
antibodies resulted specific and sensitive to their own target, and could be used for 
research experiments. Only two of the seven polyclonal antibodies failed the protein array 
validation. To improve the anti-MAPK8B and anti-CTBP2A specificity some improvements 
will be performed in the selection protocol. The new polyclonals will be tested again with 
Western blot, ELISA and protein microarray. 
 
Anti-SF3A1 (f) Anti-USP11 (g) 
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5.1.5 Comparison with commercial polyclonal antibody: anti-CDK2A 
Since that the validated polyclonal antibodies have to be used for research experiments, 
one of the yeast-purified polyclonals was compared to the correspondent commercial 
antibody available. The selected polyclonal was the anti-CDK2A. The yeast-purified and a 
commercial polyclonal rabbit antibodies directed to the full-length CDK2A protein were 
compared in ELISA and protein microarray. The following condition were used: 
commercial polyclonal at 0,2ng/μl (1:1000 dilution), commercial polyclonal at 0,07ng/μl 
(1:3000 dilution, recommended dilution) and yeast-purified polyclonal at 1ng/μl. Initially, 
the ELISA test was performed (Fig. 32). The biotinylated CDK2A and BSA were coated on a 
96 wells plate and the two anti-CDK2A polyclonals were tested on the two proteins.  
                        
Figure 32. Anti-CDK2A polyclonals comparison with ELISA test. The biotinylated CDK2A was 
coated in a 96 wells plate and revealed with: commercial polyclonal antibody at 1:1000 dilution; 
commercial polyclonal antibody at 1:3000 dilution (recommended dilution); yeast-purified 
polyclonal antibody at 1ng/μl. As control protein the BSA was used. The values were read at 
450nm, with a plate reader, and reported in the graph. 
 
From the ELISA it could be seen that the commercial, at the recommended dilution 
(1:3000), and the yeast-purified polyclonals showed comparable specificity and sensitivity 
to the CDK2A protein, indicating that our polyclonal was comparable to the commercial 
ones. As expected, the commercial polyclonal, used at higher concentration (1:1000), 
showed an higher signal than the others. In this condition, with a simple control protein as 
BSA, both polyclonals didn’t show cross-reactivity to the control protein. It has to be 
observed that the amount of the commercial antibody is lower than the yeast-purified. This 
suggested that the commercial seems more sensitive than the yeast-purified. To compare 
the antibodies on a larger number of proteins, a protein microarray was utilized. The 78 
biotinylated proteins were spotted and treated with commercial, at different 
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concentrations (0,07, 0,2, 1 ng/μl), and yeast-purified, at 1ng/μl, anti-CDK2A polyclonals. 
As positive control the streptavidin-PE was used (Fig. 33). An array scan and quantification 
were performed (Fig. 33). 
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Figure 33. Commercial and yeast-purified anti-CDK2A polyclonal comparison with protein 
array. 78 biotinylated antigens were spotted in duplicates at 50ng/μl on FAST slide. In the print 
scheme the CDK2A is depicted in red and the rabbit IgGs calibration curve in blue (15μg/ml, 
10μg/ml, 5μg/ml, 2μg/ml, 1μg/ml, 0,2μg/ml). After saturation, the PADs were treated with the 
commercial polyclonal anti-CDK2A, at 0,07, 0,2 and 1ng/μl, and the yeast-purified anti-CDK2A at 
1ng/μl. Every PAD was developed and quantified with ScanArray Gx. The values correspondent to 
pixels media-pixels background were reported in a graph as media of the duplicates spots. 
 
Figure 33 shows that the commercial polyclonal anti-CDK2A specifically recognizes its 
target protein, but also other three unspecific proteins: MAP Kinase 13A (MAPK13A), MAP 
2 Kinase 6A (MAP2K6A) and Check point Kinase 2a (CHEK2A). The unspecificity of the 
commercial polyclonal was present in all the three dilutions, confirming that these three 
proteins could be potentially recognized in standard research experiments. On the other 
hand, the yeast-purified polyclonal didn’t show any particular cross-reactivity to that three 
proteins or to the others. Furthermore, from the quantification analysis arose that the 
signal intensity of CDK2A spots in the yeast-purified PAD was comparable to the 
commercial ones. To investigate the reason why the commercial antibody recognized the  
three unspecific proteins, they were studied. First, the amminoacids sequences of CDK2A, 
MAPK13A, MAP2K6A and CHEK2A proteins were aligned, using ClastalW2 tool, to reveal 
possible common parts that could be recognized from the antibody. From this study arose 
that there weren’t any similarity in the four different proteins sequences. Subsequently, it 
was performed a research to underline possible hits patterns that could be present in all 
the proteins. Using PRATT tool it was showed that all the four proteins contain this 
particular pattern: G-[ERS]-G-[AT]-x-G-x(0,1)-V-x(4)-[DENT]-[KR]-x-[STV]-[CGP]-x(3)-[AI]-
[ILM]-[EK]-x-[AIL].  This pattern could possibly form in these proteins a conformational 
epitope that could be potentially recognized from the commercial polyclonal antibody. 
Since that the yeast-purified polyclonal anti-CDK2A didn’t cross-react with the other three 
proteins, it could be supposed that the antibodies directed to this epitope are not present 
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or are present in a very low amount. At the end, from the protein microarray analysis it 
could be affirmed that the anti-CDK2A yeast-purified polyclonal antibody could specifically 
recognize the CDK2A protein without showing any cross-reactivity. As a conclusion, five 
polyclonal antibodies selected with phage/yeast display combination method were 
validated with Western blot, ELISA and protein microarray resulting with high specificity 
and sensitivity. When used in a direct comparison the anti-CDK2A resulted better than the 
correspondent commercial available polyclonal antibody. Taken together, this show that 
this technology had a potential for the production of specific antibodies that could be more 
efficient than the commercial ones available. Finally, protein microarray technology 
confirmed to be a very important tool in the antibody validation analysis.  
 
5.2 PROTEIN ARRAY ON DEMAND ASSESSMENT 
The second aim of this project was to set up an high-throughput technology that could be 
utilized for antibody validation. As showed in the introduction protein microarray 
technology presents some drawbacks such as: production and purification of all the 
proteins tested and possible degradation of the immobilized proteins. To overcome these 
problems a new type of protein microarray called in situ protein array has been set up (Fig. 
17). In particular, this technology allows to spot cDNA that is directly transcribe and 
translate by IVTT system. To allow the capture of the newly synthetized protein a capture 
agent is also needed. With this new technology, the protein production passages are 
eliminated and the protein is tested immediately after its in situ production. The in situ 
protein array of our interest is called “protein array on demand” [74]. This technology is 
the only in situ protein array that used the DNA molecule as template and capture agent. In 
detail, “protein array on demand” is based on the capability of an E. coli protein, called TUS, 
to bind specifically a dsDNA sequence, called Ter (Fig. 34).  
                                                                  
Figure 34. TUS-Ter binding. Interaction of the TUS protein (green) with the Ter sequence (blue).  
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This in situ protein array consists in the printing of a DNA encoding for proteins of interest 
(POIs) fused to the TUS protein. The immobilized DNA is transcribed and translated with 
an IVTT system and the nascent protein directly bind to the Ter sequence, located in the 
encoded DNA molecule (Fig. 35). So, only the DNA, in form of plasmid, has to be printed on 
the array slide to perform a protein array on demand. Therefore, for this type of array, the 
template DNA construction is essential.  
                   
Figure 35. Protein array on demand. Schematic representation of the protein array on demand 
technology. A plasmid DNA containing protein of interest (pink) fused to TUS protein (light blue) 
and Ter sequence (green) is printed on an array slide. After transcription and translation with IVTT 
system of the immobilized DNA, the protein binds the DNA through TUS- Ter binding. 
 
5.2.1 Protein array on demand template construction 
As showed in figure 35, the protein array on demand is based on the DNA template 
immobilization on array slide, that encodes proteins of interest (POIs) fused to TUS and 
contains the Ter sequence. Furthermore, this DNA molecule has to be suitable for IVTT 
protein production systems. As the protein expression in the protein array on demand 
technology was carried out with an IVTT system based on rabbit reticulocyte lysate, a DNA 
vector optimized for IVTT protein production in this eukaryotic system was used. This 
particular vector is called pTNT™ (Fig. 7A) and contains:  
 T7 promoter for transcription initiation; 
 5’ β globin leader sequence and Kozak sequence as ribosome binding sites; 
 multiple cloning site (MCS) for protein of interest insertion; 
 stop codon; 
 T7 terminator for transcription ending. 
Ter 
TUS  POI 
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As a first step, it was necessary to modify the vector by inserting the TUS coding sequence. 
In particular, the TUS cDNA was inserted without the first methionin to allow its fusion 
with POIs. The strategy that was used for TUS cDNA insertion in pTNT vector was the 
following (Fig. 36): 1) extraction of E. coli genomic DNA containing the TUS cDNA; 2) 
amplification with PCR of the TUS CDS; 3) introduction with PCR of restriction sites 
(BssHII-NheI) for POIs insertion and tags for detection; 4) pTNT cloning. The resulting 
vector was called pTNT-TUS. This plasmid was transformed in DH5α cells and sequenced 
to confirm the correct DNA insertion.  
 
      
 
Figure 36. TUS cDNA insertion in the pTNT plasmid. The MCS of pTNT™ vector had to be 
modified to allow the insertion of TUS protein CDS, tags for protein detection and cloning sites for 
POIs insertion (BssHII-NheI). 1) E. coli NM522 genomic DNA extraction. 2) PCR amplification of TUS 
CDS (blue) without the first methionin codon. 3) PCR amplification of TUS CDS and addiction of 
Kozak sequence (yellow), restriction sites (black) and tags (green). 4) pTNT™ vector digestion with 
XhoI and XbaI enzymes of the PCR fragment obtained. All the PCR reactions were controlled on 
agarose gel. 
 
To perform the protein array on demand a Ter sequence had to be added to the pTNT-TUS 
vector. To improve the avidity of TUS protein to the plasmid DNA a multiple Ter sequence 
was inserted. This multiple Ter contained three Ter sequences divided by random 
nucleotides (21-22bp) (Fig. 37). This DNA fragment of 230bp was synthesized by 
GeneArt® gene synthesis as plasmid vector. The sequence of interest was extracted 
through enzymatic cut with BamHI and inserted in the pTNT-TUS vector using the same 
restriction site. This new vector was called pTNT-TUS-Ter.  
MW(bp) 
MW(bp) 
1000 
1000 
Fragment lengh: 1027bp 
1) 2) 
3) 4) 
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Figure 37. Multiple Ter sequence. A sequence containing three Ter sequences, divided by 21-22 
random nucleotides and an AgeI restriction site, was constructed. At 5’ and 3’ end was put a BamHI 
site that allowed the sequence cloning in the pTNT-TUS vector. 
Finally, the pTNT-TUS-Ter could be used for protein array on demand experiments.  
 
5.2.2 Protein expression and Ter binding 
Once obtained the suitable template for protein array on demand it was tested using four 
proteins available in our laboratory (Tab. 3). All these proteins were inserted in the pTNT-
TUS vector using BssHII and NheI as restriction sites.  
 
 
 
 
 
Table 3. POIs cloned in pTNT-TUS. Proteins already available in our laboratory used to test the 
protein array on demand. 
 
After POIs cDNA cloning, the plasmids were transformed in E. coli DH5α cells and 
sequenced. Before proceeding with the protein array on demand set up, the proteins 
expression and their Ter binding capability were tested. Proteins expression was analyzed 
with Western blot. The IVTT reaction was carried out using the T7 TnT Quick transcription 
and translation kit with 200ng of template in a final volume of 10μl. After 1h30’ at 30°C the 
reactions were denaturated with sample buffer 2x and loaded on polyacrylamide gel. The 
PROTEINS kDa 
DPP6  (Dipeptidyl-peptidase 6) 3,6 
RON2  (Macrophage stimulating 1 receptor/2) 4,7 
TG2 DM1  (Transglutaminase 2 domain 11) 47 
eGFP  (Enhancer green fluorescent protein) 23,6 
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Western blot was carried out using the anti-SV5 antibody to reveal the TUS fusion proteins 
(Fig. 38).  
                                  
      
                                                              
Figure 38. TUS fusion proteins expression with IVTT system. Schematic representation of the 
TUS fusion proteins expression by IVTT system (A). The TUS fusion proteins were produced in 10μl 
of IVTT reaction and loaded on a polyacrylamide gel at 10%: DPP6-TUS (a), RON2-TUS (b), TG2 
DM11-TUS (c), eGFP-TUS (d). After gel transfer, the nitrocellulose was developed with anti-SV5 and 
anti-mouse IgG-AP (B).  
 
From the Western blot analysis it could be observed that all the TUS fusion proteins were 
produced by IVTT system based on rabbit reticulocytes lysate. Furthermore, a very low 
protein degradation was visible, indicating that this type of protein expression system is 
efficient. Despite that, it was possible to observe that the amount of proteins were different 
even if the reaction volume and the template amount were the same. These differences 
could be related to the proteins sequence or length. After protein production assessment, it 
was necessary to confirm that this proteins were able to bind efficiently the Ter sequence. 
To test it, an ELISA, in a low volume 384 wells plate, was set up. The molecule coated in the 
ELISA well was a DNA fragment, able to express POIs fused to TUS as well as containing the 
Ter sequence for protein immobilization (Fig. 39A). This DNA fragment was obtained 
through PCR amplification using pTNT-TUS vector as template. This PCR DNA was 
immobilized wells through streptavidin-biotin binding on the ELISA. Since that the PCR 
DNA amount necessary for proteins expression and Ter binding was unknown, an ELISA 
POI 
SV5 
TUS 
A) 
B) 
28 
36 
55 
72 
95 
130 
MW a b c d 
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set up was performed. After streptavidin coating, different concentrations of PCR DNA, 
encoding for eGFP-TUS protein, (200, 400, 600, 800, 1000, 1500, 2000 ng) were used for 
DNA immobilization set up. After 1h binding, the DNA was recovered from the plate and 
loaded on agarose gel (Fig. 39B). To understand the amount of DNA bound on the plate a 
DNA calibrator was used. Subsequently, the eGFP-TUS protein, already produced with IVTT 
system, was added to the same ELISA wells and incubated for 1h. The anti-SV5 was used 
for protein detection (Fig. 39C). As negative control a PCR DNA lacking the Ter sequence 
was used. 
                              
                             
            
Figure 39. ELISA set up for TUS-Ter binding study. To verify the TUS-Ter binding an ELISA test 
was set up. A) PCR DNA fragment, immobilized on the ELISA wells, containing: all sequences 
necessary for IVTT (T7 promoter, Kozak, T7 terminator), eGFP-TUS coding sequence, Ter sequence 
at 3’ end and biotin at 5’ end. B) Different concentrations of PCR DNA (200, 400, 600, 800, 1000, 
1500, 2000 ng) were incubated with streptavidin coated wells for 1h. After the incubation the DNA 
was recovered and compared on an agarose gel to a DNA calibrator. C) After PCR immobilization 
the eGFP-TUS protein, produced with IVTT system, was incubated in the same wells for 1h. The 
protein bound to DNA was detected with anti-SV5 at 1:5000 dilution. As negative control a PCR 
without Ter sequence was used. 
 
From the agarose gel it could be observed that the higher amount of PCR DNA that can be 
captured from the streptavidin coated well was 400ng (Fig. 39B). Observing the protein 
detection results (Fig. 39C) it could be evident that the higher amount of protein was 
bound to the well correspondent to 2000ng PCR DNA. Despite that, the correspondent 
negative control was also high compared to the other tested conditions. For this reason, in 
the further experiments will be used 1000ng PCR amount. Indeed, this condition 
corresponded to the higher amount of protein detection and the lower background signal. 
DNA calibrator Recovered DNA  
A) 
B) C) 
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After calibration set up, the same ELISA was performed for all the other TUS fusion 
proteins (DPP6, RON2, TG2DM11) (Fig. 40). The experiment was repeated for three times 
in order to performed a statistical analysis. 
 
 
 
 
 
 
 
 
Figure 40. TUS-Ter binding test. For all the proteins cloned in pTNT-TUS was performed the 
ELISA test previously showed. As negative control an IVTT mix without template was used. The 
results were expressed as the media of three different experiments. A statistical analysis with t-
Student test was performed (* = p<0,01, ** =p<0,001). 
 
This analysis confirmed that different TUS fusion proteins could efficiently bind to Ter 
sequence. Furthermore, this binding was resulted statistically significant for all the 
proteins tested. Finally, could be confirmed that our vector allowed the expression of TUS 
fusion proteins, with IVTT system, that were able to bind specifically the Ter sequence.  
 
5.1.3 Protein array on demand 
After TUS fusion proteins production and Ter binding assessment, the protein array on 
demand was performed [74]. The plasmid DNA encoding for TUS-fusion proteins with and 
without multiple Ter sequence were printed on FAST slide, heated at 80°C, for DNA 
entrapment, and dried overnight at room temperature. Three different analysis were 
performed: I) PicoGreen staining, for immobilized dsDNA detection (Fig. 41A) II) POIs-TUS 
binding to immobilized pTNT-TUS-Ter detection(Fig. 41B); III) POIs-TUS expression from 
immobilized DNA and their subsequent binding to pTNT-TUS-Ter detection (protein array 
on demand) (Fig. 41C). The POIs-TUS binding to pTNT-TUS-Ter was assessed through 
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POIs-TUS expression from a not immobilized plasmid DNA. The proteins was detected with 
the anti-SV5 antibody.  
                                             
 
 
 
Figure 41. Protein array on demand. pTNT-TUS and pTNT-TUS-Ter plasmids, encoding for DPP6-
TUS, RON2-TUS, TG2 DM11-TUS and eGFP-TUS, were printed on FAST slide. On the same slide, 
three experiments were performed: A) PicoGreen staining; B) expression of eGFP-TUS with TnT 
Quick IVTT from 200ng of pTNT eGFP-TUS in solution; C) expression of all the four tested proteins 
with TnT Quick IVTT from immobilized DNA (protein array on demand). In the upper part a 
schematic representation of the experiment is shown. Proteins were detected with the anti-SV5 
antibody.  
 
The PicoGreen staining confirmed that dsDNA could be efficiently bound to nitrocellulose 
slides (Fig. 41A). When the TUS protein was expressed from not immobilized DNA, it could 
be efficiently captured from the Ter sequence (Fig. 41B). Furthermore, where the Ter 
sequence was absent the protein was completely undetected. From the protein array on 
demand could be observed that all the TUS fusion proteins were produced from 
immobilized DNA and subsequently bound the DNA carrying the Ter sequence (Fig. 41C). 
Finally, it could be affirmed that the Chatterjee’s protein array on demand is functional. 
Despite that, the signals were very low and sometimes not visible. These results suggested 
A) B)  C)  
Ter POI SV5 TUS 
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that the protein array on demand wasn’t well established and enough sensitive to be used 
for our purpose: antibodies validation analysis.   
 
5.3 SET UP OF A NEW PROTEIN ARRAY ON DEMAND PROTOCOL 
Since that the published protein array on demand seems not reproducible and enough 
sensitive, a new protein array on demand protocol, suitable for high-throughput antibody 
validation, was set up. Our hypothesis was that the reduced reproducibility of protein array 
on demand was dependent on DNA accessibility for the IVTT system. It was possible that 
IVTT's enzymes and ribosomes couldn’t reach the spotted DNA and perform its 
transcription and translation. For this reason, we looked for improved conditions for an 
efficient IVTT from immobilized DNA by evaluating different array slides and DNA 
templates. 
 
5.3.1 Array slide and DNA template set up 
Different slides able to bind covalently the DNA were evaluated. These slides are coated 
with particular reactive groups, such as: epoxysilane, aldehydesilane, aminosilane and N-
hydroxysuccinimide (Fig. 42). All these groups are able to form covalent binding with other 
chemical groups: 
 Epoxysilane binds: Amino, thiol and hydroxyl groups; 
 Aldehydesilane binds: amino groups; 
 Aminosilane binds: positively charged groups; 
 N-hydroxysuccinimide binds: amino groups. 
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Figure 42. DNA binding slides. Different types of slides able to bind modified or not modified DNA 
molecules. 
 
Since that epoxysilane and aminosilane slides bound randomly the DNA molecule itself, 
causing possible modifications, they were excluded. The remaining slides were able to bind 
the same chemical group (NH2). As slides covered with N-hydroxysuccinimide were 
already used in another type of in situ protein array [93], it was decided to use these slides 
for our new protein array on demand. In particular, the Authors had used CodeLink® 
slides which present the reactive groups included in a 3D gel matrix. To immobilized the 
DNA on CodeLink® slide an NH2 group had to be added. Three different DNA printing 
strategies were carried out to allow DNA immobilization (Fig. 43): 
 Amino-modified PCR products; 
 Biotinylated PCR products; 
 Biotinylated PCR products mix with streptavidin. 
 
                                                                                                           
 
 
Figure 43. modified DNA molecules spotted on CodeLink® slides. Three different DNA 
molecules were printed on CodeLink slides: A) Amino-modified PCR DNA; B) Biotinylated PCR 
DNA; C)Biotinylated PCR DNA mixed with streptavidin. The PCR DNA was compatible for IVTT 
expression of TUS fusion proteins. 
Epoxysilane Aldehydesilane Aminosilane N-hydroxysuccinimide 
A) B) C) 
POI SV5 TUS Biotin Streptavidin 
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The same PCR product was produced adding at 5’end an NH2 group or a biotin through 
amino-modified or biotinylated primers (pTNT seq). The amplified PCR DNA was suitable 
for IVTT expression of TUS fusion proteins. In case of biotinylated PCRs a preliminary 
incubation of 10’ with 5μg of streptavidin was carried out. PCRs encoding for DPP6, RON2, 
TG2 DM11 and eGFP fused to TUS, containing or not the Ter sequence, were spotted on 
CodeLink® slide. For all the three printing conditions were tested (Fig. 44): I) dsDNA 
immobilization with PicoGreen staining; II) the TUS fusion proteins expression and 
subsequent Ter binding. 
       
 
Figure 44. DNA template set up. Three different modified PCR DNA, encoding for DPP6, RON2, 
TG2 DM11 and eGFP fused to TUS, were printed on CodeLink® slide: A) Amino-modified PCR DNA; 
B) Biotinylated PCR DNA; C) Biotinylated PCR DNA preincubated with streptavidin. For every type 
of template a PicoGreen staining and a protein array on demand with TnT Quick for PCR DNA were 
performed. The proteins were detected with the anti-SV5 antibody. 
 
From this experiment it could be observed that all the three types of PCRs DNA were 
efficiently immobilized on CodeLink® slides. In particular, the biotinylated PCR DNA 
previously incubated with streptavidin showed the better spots shape and DNA 
homogeneous distribution than the other conditions (Fig. 44C). Observing the three 
protein arrays on demand (Fig. 44), the biotinylated PCR DNA mixed with streptavidin was 
the only condition that allowed the transcription and translation of proteins from 
immobilized DNA. Furthermore, the expressed proteins were efficiently captured from the 
DNA carrying the Ter sequence. To confirm its reproducibility the experiment was 
repeated for three times. In conclusion, the new protein array on demand, in which 
A) 
On demand On demand On demand PicoGreen PicoGreen PicoGreen 
B) C) 
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biotinylated PCRs were incubated with streptavidin and printed on CodeLink® slide, was 
set up.  
 
5.3.2 Protein array on demand improvements 
After protein microarray on demand set up some improvements were performed, in order 
to reach the best conditions. In particular, the printing conditions and the protein 
production with IVTT were analyzed. To increase the amount of immobilized DNA, 
different printing conditions were tested. The same 5’-biotinylated PCR DNA, encoded for 
eGFP-TUS, was mixed with: 
1) 3μg streptavidin; 
2) 3μg streptavidin, 0,005% triton-X; 
3) 1μg streptavidin, 0,005% triton-X; 
4) 1μg streptavidin, 10μg BSA; 
5) 1μg streptavidin, 10μg BSA, 0,005% triton-X. 
All these five printing conditions were spotted on CodeLink® slide together with the 
CodeLink printing buffer at 1x or 2x concentration. After DNA spotting the slide was 
stained with PicoGreen to assess spots shape and amount of printed DNA (Fig. 45). A 
protein array on demand was carried out to compare the amount of protein produced and 
bound for all the printing conditions (Fig. 45). 
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Figure 45. DNA printing improvement. The same biotinylated PCR DNA with or without Ter 
sequence, encoding for eGFP-TUS protein was printed on CodeLink® slide with different printing 
strategies: a) 1μg streptavidin, 10μg BSA, 0,005% triton-X; b) 3μg streptavidin, 0,005% triton-X; c) 
1μg streptavidin, 0,005% triton-X; d) 3μg streptavidin; e) 1μg streptavidin, 10μg BSA. All these 
conditions were diluted in CodeLink printing buffer 1x or 2x. PicoGreen staining and protein array 
on demand, with anti-SV5 staining, were carried out. 
 
The PicoGreen staining revealed that the use of triton-X didn’t improve the DNA 
immobilization on this kind of slides. Indeed, the DNA resulted less concentrated and non-
homogeneously distributed where 0,005% of triton-X was used. On the other hand, the mix 
of streptavidin and BSA showed a good DNA immobilization with an homogeneous 
distribution as in presence of 1x or 2x printing buffer. Finally, the streptavidin alone 
resulted less efficient in DNA immobilization when the printing buffer 1x was used, but was 
efficient when used with 2x buffer. Furthermore, observing the correspondent protein 
array on demand the condition that allowed the major amount of protein production and 
binding was the one with biotinylated PCRs mixed with streptavidin and printing buffer 2x. 
In conclusion, the 5’-biotinylated PCRs mixed with 3μg of streptavidin and diluted in 
CodeLink print buffer 2x was the best achieved condition for DNA printing and protein 
array on demand development. Another evaluated aspect was the IVTT protein expression. 
Till now all the protein arrays on demand were performed using an IVTT system based on 
rabbit reticulocytes lysate, but other eukaryotic IVTT systems, based on other cell type, are 
today available, such as wheat germ and HeLa cell lysate. To understand the capability of 
these IVTT systems an analysis were done. First, it was necessary to construct a DNA 
template suitable for HeLa cells IVTT system. For this type of IVTT the T7 prometer and the 
Kozak sequence are insufficient for protein expression. The insertion of an 
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encephalomyocarditis virus (ECMV) internal ribosome entry site (IRES), downstream of 
the T7 promoter, was necessary. This IRES sequence was cloned into the pTNT vector. The 
correspondent plasmid was called pIRES-TUS. To compare the efficiency of the different 
IVTT systems a Western blot analysis was done. The same protein, eGFP-TUS, was 
expressed with the three different IVTT systems, in 10μl of reaction, following the kit 
protocols. The reactions were denaturated, loaded on polyacrylamide gel and analyzed 
with Western blot (Fig. 46A). The eGFP-TUS protein was revealed with the anti-SV5 and the 
resulting bands were quantified with the Imagej software (Fig. 46B).  
 
              
                                                                                                    
Figure 46. Protein production improvement. The eGFP-TUS protein was produced with IVTT 
base on: HeLa cell, wheat germ (WG) and rabbit reticulocytes (RRL) lysates. The protein produced 
in 10μl of reaction was denaturated and loaded on polyacrylamide gel. A) Western blot analysis 
performed with anti-SV5 staining and anti-mouse IgG-AP. B) Western blot bands quantification 
with Imagej software.  
 
Looking at the Western blot analysis seems that the HeLa cell lysate gave the major amount 
of proteins and also the less amount of protein degradation, compared to the other two 
systems. To verify the capability of HeLa cell lysate in our protein array on demand PCRs, 
encoding for DPP6, RON2, TG2 DM11 and eGFP fused to TUS, containing or not the Ter 
sequence, were spotted at the previously described conditions. Two different protein 
arrays on demand were performed, one with T7 TnT Quick for PCR DNA and the other with 
1-Step Human coupled in vitro expression kit (Fig. 47). 
A) 
eGFP-TUS production
0
500000
1000000
1500000
HeLa WG RRL
B) 
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Figure 47. RRL/HeLa protein array on demand. Biotinylated PCRs with or without IRES 
sequence were spotted at 400ng/μl with streptavidin and printing buffer 2x. The PCRs encoded for 
DPP6, RON2, eGFP, TG2 DM11 fused to TUS and contained or not the Ter sequence. The DNA 
containing the IRES sequence was treated with HeLa cell lysate IVTT, whereas the ones containing 
only the Kozak sequence was treated with rabbit reticulocytes lysate IVTT. After in situ protein 
production an anti-SV5 staining was performed. The arrays were scanned with ScanArray Gx. 
 
The protein arrays showed that the HeLa cell lysate didn’t allow the expression of the 
eGFP-TUS protein from the immobilized DNA, impeding the protein array on demand 
production (Fig. 47). On the other hand, the rabbit reticulocytes lysate confirmed its 
capability to perform an in situ protein production from spotted DNA. In conclusion, the 
final condition to produce a protein array on demand are: 
 Template: 400ng/μl of biotinylated PCRs DNA mixed with 3μg of streptavidin in 
CodeLink buffer 2x; 
 Support: CodeLink® slide; 
 IVTT system: rabbit reticulocytes lysate. 
 
5.2.4 Protein array on demand 
Since that the protein array on demand was set up an antibody validation test was done. 
The PCRs DNA encoding for DPP6, RON2, TG2 DM11 and eGFP fused to TUS, containing or 
not the Ter sequence, were spotted at the optimized conditions. Two protein arrays on 
demand were performed (Fig. 48): 
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1. with anti-SV5 staining, where all the proteins had to be recognized; 
2. with anti-GFP staining, where only the eGFP-TUS had to be detected. 
 
   
Figure 48. Protein array on demand with anti-GFP. PCRs DNA, with or without Ter sequence, 
encoding for DPP6, RON2, TG2 DM1 and eGFP fused to TUS were spotted on CodeLink slide. A) 
PicoGreen staining; B) Protein array on demand with anti-SV5 staining; C) Protein array on demand 
with anti-GFP staining. 
 
From these arrays could be observed that all the four proteins were produced and bound 
specifically to the DNA containing the Ter sequence. On the other hand, when the anti-GFP 
was used there wasn’t seen any signal in correspondence of the eGFP-TUS protein. To 
investigate if the problem was related to the anti-GFP binding to eGFP-TUS protein, an 
IVTT mix plus 200ng of eGFP-TUS PCR DNA in solution was used on the same array slide to 
allow a higher amount of eGFP-TUS protein production and binding to Ter (Fig. 49). 
 
                                                
Figure 49. eGFP-TUS protein array on demand with DNA in solution. The previously tested 
slide was treated with IVTT mix containing 200ng of PCR DNA, encoding for eGFP-TUS protein, in 
solution. After protein expression and binding the anti-GFP antibody was used.  
A) PicoGreen B) Anti-SV5 C) Anti-GFP 
Anti-GFP 
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As expected, the eGFP-TUS could be specifically recognized from the correspondent 
antibody. The second aspect that was studied the  steric hindrance. Indeed, it was possible 
that the protein, once produced and captured on the slide, remained enclosed through the 
PCR DNA molecules, leading to an unavailability of the protein to the correspondent 
antibody. To increase the space between the immobilized DNA molecules different 
concentrations of BSA were added to the PCRs. Indeed BSA could compete with 
streptavidin for the N-hydroxysuccinimide binding. This competition could lead to a DNA 
molecules spreading. The PCR DNA encoding for eGFP-TUS protein was spotted on 
CodeLink slide with different concentration of streptavidin and BSA (Fig. 47). 
 
              
47. Protein array on demand with BSA addiction. The PCRs DNA encoding for eGFP-TUS or 
RON2-TUS proteins were printed on CodeLink slide in different printing conditions: 1. 3μg 
streptavidin, 25μg BSA; 2. 3μg streptavidin, 20μg BSA;3. 2μg streptavidin, 10μg BSA;4. 2μg 
streptavidin, 20μg BSA; 5. 1μg streptavidin, 15μg BSA. Two protein arrays on demand were 
performed and depicted with: A) anit-SV5 staining; B)anti-GFP staining. As negative control a PCR 
without Ter was used. 
 
The anti-SV5 stained protein array on demand revealed that both eGFP-TUS and RON2-TUS 
were produced. Furthermore, using the anti-GFP staining, only the spots correspondent to 
eGFP-TUS protein were positives. In particular, two printing conditions (3 and 5) seem 
better that the others tested. Obviously, it could be also seen that the signal due to the anti-
GFP antibody was lower than the anti-SV5 ones. This aspect suggested that this wasn’t the 
best condition to perform a protein array on demand, but showed that the printing 
conditions were responsible for the achievement of a good protein array on demand.  
 
 
A) Anti-SV5 A) Anti-GFP 
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6. DISCUSSION 
 
Antibodies are crucial molecules in scientific research in particular for proteomic studies. 
To perform a good study a very specific and sensitive antibody is needed. These antibodies 
features depend on a good antibody validation. For this reason our purpose is to validate 
different polyclonal antibodies, in form of scFv-Fc, with high-throughput methods.  
 
6.1 POLYCLONAL ANTIBODIES VALIDATION  
In collaboration with Bradbury’s group a list of 78 proteins was filled out, based on 
proteins solubility and structure. The first seven proteins of the list (Tab. 2) were used for 
polyclonals selection with two rounds of phage display and two rounds of yeast display. 
The selected polyclonal antibodies were cloned in a yeast vector and produced as scFv-Fc 
rabbit. Three different analysis were performed for antibodies validation: Western blot, 
ELISA and protein microarray. From the Western blot analysis five polyclonal supernatants 
resulted able to recognize specifically their target protein without reacting to the control 
ones (Fig. 24). Only two antibodies (anti-CTBP2A, anti-MAPK8B) have shown no binding 
activity to their antigens. This result was explained by an antibodies specificity directed 
only to conformational epitopes. To confirm this hypothesis an ELISA validation was 
performed (Fig. 25). In the ELISA, all antibodies were tested simultaneously with all the 
seven antigens to validate their specificity on an higher number of proteins. The values 
reported in the graph demonstrated that all the polyclonals were specific to their own 
antigen and didn’t present cross-reactivity to the other proteins tested (Fig. 25). As 
expected, the two polyclonals not functional in Western blot, resulted positive in the ELISA, 
confirming their ability to recognize the target only in the conformational form. 
Furthermore, from this validation it could be observed that the polyclonal antibodies 
presented different sensitivity to the target. Evaluating the antibodies concentration in the 
supernatants it was observed that the antibodies sensitivity was proportional to the 
supernatants concentration (Fig. 26). Finally, the ELISA validation has revealed that all the 
tested polyclonals were positive even if presented different sensitivity. As previously 
described, the Western blot and the ELISA analysis are not sufficient for a good antibody 
validation. For this reason, the protein microarray technology was used as major sensitive 
and largest samples screened toll (Fig. 29-30). The protein array showed that six 
polyclonals supernatants were able to recognize specifically their own antigen, even if with 
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different sensitivity. Indeed, anti-CDK2A, anti-MAPK2A5 and anti-USP11 polyclonals gave 
high signals, instead anti-PLAA, anti-SF3A1 and anti-MAPK8B showed weak signals. This 
could be related to a lower antibodies concentration, indeed, two of them presented a 
lower amount of antibodies in ELISA compared to the others. To validate in a correct way 
the polyclonal antibodies they were purified and tested with a second protein array 
analysis (Fig. 31). This new protein array showed that the five polyclonals anti-CDK2A, 
anti-MAPK2A5, anti-USP11, anti-PLAA and anti-SF3A presented high specificity and 
sensitivity to the target proteins. Furthemore, none of them showed cross-reactivity to 
other proteins. Unfortunately, the anti-MAPK8B and anti-CTBP2A were not efficient even in 
the purified form. The anti-CTBP2A recognized its target but also the MAPK2A5; the anti-
MAPK8B didn’t react to its antigen. The problem of these polyclonal antibodies could be 
related to the selection method or to a not efficient antibody production. To study this 
aspect new select and production will be performed for this two antibodies. The new 
polycloanls will be tested on protein array. In conclusion, five polyclonal antibodies 
produced with the phage/yeast display combination method resulted specific and sensitive 
in Western blot, ELISA and protein microarray. Only two antibodies, anti-CTBP2A and anti-
MAPK8B, seem unfunctional in Western blot and protein array, but recognized the target in 
the ELISA validation. To confirm the potential of this new antibody selection method, a 
yeast-purified polyclonal antibody was compared to the commercial ones. The yeast-
purified anti-CDK2A was tested in ELISA and protein array, together with its 
correspondent commercial antibody. The ELISA showed that the yeast-purified and the 
commercial polyclonals present comparable specificity and sensitivity to CDK2A protein 
(Fig. 32). Looking at the protein array analysis it was observed that the yeast-purified 
antibody was better than the commercial ones (Fig. 33). Indeed, the commercial anti-
CDK2A bound other three unspecific proteins: MAP Kinase 13A (MAPK13A), MAP 2 Kinase 
6A (MAP2K6A) and Check point Kinase 2a (CHEK2A). Studying the sequences of these 
proteins arose that they don’t show an alignment, but watching at the proteins patters with 
Expasy prosite tool they contain all the following pattern: G-[ERS]-G-[AT]-x-G-x(0,1)-V-
x(4)-[DENT]-[KR]-x-[STV]-[CGP]-x(3)-[AI]-[ILM]-[EK]-x-[AIL].  This pattern can allow the 
formation of a conformational epitope that can be possibly recognized by the commercial 
anti-CDK2A antibody. On the other hand, the yeast-purified antibody didn’t show cross-
reaction to these three proteins or to the others, maintaining an high sensitivity to the 
target protein. This final analysis confirmed that the phage/yeast display combination is a 
very specific and successful method for high specific polyclonal antibodies selection. 
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Furthermore, protein array technology confirming its efficiency as antibodies validation 
tool. Obviously, other technologies as immunohystochemistry and immunofluorescence are 
needed to confirm the real specificity of these antibodies. 
 
6.2 PROTEIN ARRAY ON DEMAND  
Protein array technology is very important and useful tool for many different applications, 
such as antibodies validation. Despite that, protein array has also some drawbacks: 1. 
proteins production and purification processes have to be performed for all the printed 
proteins; 2. proteins can go on degradation after their immobilization on slides. To 
overcome these problems a new type of protein microarray has been set up, called in situ 
protein array [75]. This new technology consists of (Fig. 17): 1. printing of the proteins 
cDNA on the array slide; 2. transcription and translation of the printed DNA through IVTT 
systems; 3. capturing of the nascent proteins; 4. revealing of the proteins. In the last 
decade, many types of in situ protein arrays, differing each other for DNA template and 
capture agent used, have been developed [72; 73; 74; 75; 76; 77; 100]. The in situ protein 
array of our interest is called “protein array on demand” [74]. This array exploits the role of 
an E. coli protein called TUS to bind specifically a dsDNA sequence called Ter [82]. The 
peculiarity of this array is the presence of the template and the capture agent in the same 
DNA molecule (Fig. 35). Our aim was to use this protein array for high-throughput 
antibodies validation. The pTNT™ commercial vector, optimized for protein expression 
with rabbit reticulocytes lysate IVTT systems, was modified to insert (Fig. 36): I) TUS 
protein cDNA without methionin; II) two enzyme restriction sites (BssHII-NheI), for 
protein of interest insertion; III) SV5 and His6 tags, for protein detection. After plasmid 
modification, a set of four proteins, available in our laboratory, were inserted in this new 
plasmid called pTNT-TUS (Tab. 3). The expression of these TUS fusion proteins, with rabbit 
reticulocytes lysate IVTT, were tested by Western blot (Fig. 38). This analysis confirmed 
that the pTNT-TUS plasmid was suitable for TUS fusion proteins expression through rabbit 
reticulocytes lysate IVTT system. Furthermore, a low proteins degradation were observed. 
After proteins expression assessment the ability of that proteins to bind the Ter sequence 
was investigated. An ELISA test for TUS-Ter binding evaluation was set up using eGFP-TUS 
as control protein (Fig. 39).  Subsequently, the ELISA was performed for all the four TUS 
fusion proteins (Fig. 40). The results showed that all the TUS fusion proteins could bound 
specifically to the Ter sequence. After the protein production and binding evaluation a 
protein array on demand was performed. The pTNT-TUS and pTNT-TUS-Ter plasmid were 
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spotted on FAST slide. Three different analysis were performed (Fig. 41): 1. PicoGreen 
staining, for dsDNA printing evaluation (Fig. 41A); 2. protein expression with T7 TnT Quick 
plus eGFP-TUS plasmid in solution, for TUS-Ter binding evaluation on array slide (Fig. 
41B); 3. protein production with T7 TnT Quick using the immobilized DNA as template, for 
protein array on demand assessment (Fig. 41C). All the four proteins were detected with 
anti-SV5 antibody. The PicoGreen staining showed that dsDNA could be efficiently 
immobilized on nitrocellulose. The figure 41B confirmed that TUS fusion proteins could be 
efficiently captured by DNA carrying Ter sequence. Finally, the protein array on demand 
showed the expression of TUS fusion proteins from immobilized DNA and their cupture by 
Ter sequence. Despite that, the proteins signals were weak and sometimes not detectable. 
These results showed that the protein array on demand wasn’t enough sensitive for our 
purpose. For this reason a new protein array on demand protocol was set up.  
 
6.3 NEW PROTEIN ARRAY ON DEMAND SET UP 
To perform a new protein array on demand was necessary set up the array slide and the 
DNA template. Between the slides able to immobilized DNA the one cover with N-
hydroxysuccinimide group were used. In particular, CodeLink® slides were used for the 
following experiments. Three different templates were tested on this slides (Fig. 43): 1. 
Amino-modified PCR DNA; 2. Biotinylated PCR DNA; 3. Biotinylated PCR DNA mixed with 
streptavidin. For these three conditions a PicoGreen staining and a protein array on 
demand were performed (Fig. 44). This experimet showed that the biotinylated PCR DNA 
preincubated with streptavidin was the only condition that allowed a protein array on 
demand production. Further improvements were performed: DNA printing and IVTT 
protein production. From the printing optimization arose that the best DNA immobilization 
and protein array on demand were reached in presence of biotinylated PCR DNA premixed 
with 3μg of streptavidin (Fig. 45). In the protein expression optimization the best IVTT 
system for our protein array on demand was the one based on rabbit reticulocytes lysate 
(Fig. 47). Once optimized the protein array on demand, its antibody validation ability was 
tested. An anti-GFP monoclonal antibody were used to reveal the presence of the eGFP-TUS 
protein on the array (Fig. 48). The protein array on demand was developed with anti-SV5 
and anti-GFP. Surprisingly, only the anti-SV5 staining was positive. Our idea regarding this 
problem was related to steric hindrance. Indeed, it was possible that the protein was 
unavailable to its antibody because the PCR DNA molecules surround it. Based on this idea, 
the BSA was added to the printing solution to increase the space between the PCR DNA 
 82 
molecules (Fig. 49). Different concentrations of streptavidin and BSA were tested with the 
same PCR DNA template. Protein arrays on demand with anti-SV5 and anti-GFP staining 
were performed. The arrays showed that the addition of BSA allowed a binding between 
eGFP-TUS and its antibody. Even if this signal was lower than the anti-SV5 one, it 
represented an improvement in the protein array on demand. In conclusion, it could be 
asserted that a new protein array on demand has been set up and it is functional and 
reproducible.  
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